##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
 FORM 10-Q (Mark One) þ
    
    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 For the quarterly period ended March 31, 2005 OR o
    
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
 For the transition period from   to . Commission File No. 1-15803 AVANIR PHARMACEUTICALS  California
(State or other jurisdiction of
incorporation or organization)
    
    33-0314804
(I.R.S. Employer Identification No.)11388 Sorrento Valley Road, San Diego, California
(Address of principal executive offices)
    
    92121
(Zip Code)
 (858) 622-5200
(Registrants telephone number, including area code) Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or
for such shorter periods that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.   YES  þ  NO  o Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of
the Exchange Act).   YES  þ  NO  o As
of May 12, 2005, the registrant had 107,556,197 shares of Class A common stock issued and
outstanding.




---



Table of Contents PagePART I. FINANCIAL INFORMATIONItem 1. Financial StatementsReport of Independent Registered Public Accounting Firm
    
    
    3Condensed Consolidated Balance Sheets
    
    
    4Condensed Consolidated Statements of Operations
    
    
    5Condensed Consolidated Statements of Cash Flows
    
    
    6Notes to Condensed Consolidated Financial Statements
    
    
    7Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    
    17Item 3. Quantitative and Qualitative Disclosures about Market Risk
    
    
    40Item 4. Controls and Procedures
    
    
    40PART II. OTHER INFORMATIONItem 1. Legal Proceedings
    
    
    41Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
    
    
    41Item 3. Defaults Upon Senior Securities
    
    
    41Item 4. Submission of Matters to a Vote of Security Holders
    
    
    41Item 5. Other Information
    
    
    42Item 6. Exhibits
    
    
    42Signatures
    
    
    42CertificationsEXHIBIT 10.1EXHIBIT 10.2EXHIBIT 10.3EXHIBIT 15.1EXHIBIT 31.1EHXIBIT 31.2EXHIBIT 32.1EXHIBIT 32.2
  2




---



##### Table of Contents



PART I. FINANCIAL INFORMATION 
 Item 1. FINANCIAL STATEMENTS 
 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and ShareholdersAvanirPharmaceuticals We have reviewed the accompanying condensed consolidated balance sheet of Avanir
Pharmaceuticals and subsidiaries (the Company) as of March 31, 2005, and the related condensed
consolidated statements of operations for the three-month and six-month periods
ended March 31, 2005 and 2004, and of cash flows for the
six-month periods ended March 31, 2005 and 2004. These interim financial statements are the responsibility of the
Companys management. We
conducted our reviews in accordance with the standards of the Public Company Accounting Oversight
Board (United States). A review of interim financial information consists principally of applying
analytical procedures and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in
accordance with the standards of
the Public Company Accounting Oversight Board (United States), the objective of which is the
expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do
not express such an opinion. Based on our reviews, we are not aware of any material modifications that should be made to such
condensed consolidated interim financial statements for them to be in conformity with accounting
principles generally accepted in the United States of America. We have previously audited, in accordance with standards of the Public Company Accounting Oversight
Board (United States), the consolidated balance sheet of the Company as of September 30, 2004, and
the related consolidated statements of operations, shareholders equity, and cash flows for the
year then ended (not presented herein); and in our report dated December 13, 2004, we expressed an
unqualified opinion on those consolidated financial statements. In our opinion, the information
set forth in the accompanying condensed consolidated balance sheet as of September 30, 2004 is
fairly stated, in all material respects, in relation to the consolidated balance sheet from which
it has been derived. DELOITTE & TOUCHE LLP San Diego, California
May 13, 2005 3




---



##### Table of Contents



AVANIR Pharmaceuticals 
 CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) 
 March 31,
    
    
    September 30,2005
    
    
    2004ASSETSCurrent assets:Cash and cash equivalents
    
    $
    8,206,486
    
    
    $
    13,494,083Short-term investments in securities
    
    
    5,050,680
    
    
    
    8,803,982Receivables, net
    
    
    320,997
    
    
    
    239,879Inventory
    
    
    6,200
    
    
    
    9,302Prepaid expenses
    
    
    2,137,501
    
    
    
    1,526,282Total current assets
    
    
    15,721,864
    
    
    
    24,073,528Investments in securities
    
    
    2,852,249
    
    
    
    2,751,867Restricted investments in securities
    
    
    856,597
    
    
    
    856,597Property and equipment, net
    
    
    5,826,010
    
    
    
    6,390,964Intangible assets, net
    
    
    3,307,104
    
    
    
    3,035,024Other assets
    
    
    286,035
    
    
    
    295,973TOTAL ASSETS
    
    $
    28,849,859
    
    
    $
    37,403,953LIABILITIES AND SHAREHOLDERS EQUITYCurrent liabilities:Accounts payable
    
    $
    1,739,572
    
    
    $
    1,961,938Accrued expenses and other liabilities
    
    
    3,756,894
    
    
    
    2,418,209Accrued compensation and payroll taxes
    
    
    800,899
    
    
    
    710,368Current portion of deferred revenue
    
    
    1,932,894
    
    
    
    1,961,530Current portion of notes payable
    
    
    316,856
    
    
    
    211,092Current portion of capital lease obligations
    
    
    92,295
    
    
    
    156,770Total current liabilities
    
    
    8,639,410
    
    
    
    7,419,907Deferred revenue, net of current portion
    
    
    18,048,076
    
    
    
    19,047,585Notes payable, net of current portion
    
    
    580,465
    
    
    
    703,560Capital lease obligations, net of current portion
    
    
    22,816
    
    
    
    35,642Total liabilities
    
    
    27,290,767
    
    
    
    27,206,694COMMITMENTS AND CONTINGENCIES(Note 13)SHAREHOLDERS EQUITY:Preferred stock  no par value, 10,000,000 shares
authorized, no shares issued and outstanding as of
March 31, 2005 and September 30, 2004
    
    
    
    
    
    
    Common stock  no par value, Class A, 200,000,000
shares authorized, 99,786,197 and 95,305,757
shares issued and outstanding as of March 31, 2005
and September 30, 2004, respectively
    
    
    147,189,433
    
    
    
    134,687,535Accumulated deficit
    
    
    (145,545,438
    )
    
    
    (124,405,902
    )Accumulated other comprehensive loss
    
    
    (84,903
    )
    
    
    (84,374
    )Total shareholders equity
    
    
    1,559,092
    
    
    
    10,197,259TOTAL LIABILITIES AND SHAREHOLDERS EQUITY
    
    $
    28,849,859
    
    
    $
    37,403,953
 See notes to consolidated financial statements. 4




---



##### Table of Contents



AVANIR Pharmaceuticals 
 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) 
 Three months ended
    
    
    Six months endedMarch 31,
    
    
    March 31,2005
    
    
    2004
    
    
    2005
    
    
    2004REVENUES:Royalties and sale of royalty
rights (Note 6)
    
    $
    419,816
    
    
    $
    347,017
    
    
    $
    930,130
    
    
    $
    885,513Research contracts and licenses
    
    
    100,000
    
    
    
    267,500
    
    
    
    300,000
    
    
    
    270,500Government research grants
    
    
    124,917
    
    
    
    241,320
    
    
    
    285,568
    
    
    
    439,531Product sales
    
    
    
    
    
    
    
    
    
    
    17,400
    
    
    
    769,938Total revenues
    
    
    644,733
    
    
    
    855,837
    
    
    
    1,533,098
    
    
    
    2,365,482OPERATING EXPENSES:Research and development
    
    
    11,428,170
    
    
    
    5,375,760
    
    
    
    16,482,411
    
    
    
    10,742,129General and administrative
    
    
    1,973,792
    
    
    
    1,507,213
    
    
    
    3,825,967
    
    
    
    2,912,423Sales and marketing
    
    
    1,398,391
    
    
    
    722,086
    
    
    
    2,497,219
    
    
    
    1,580,597Cost of product sales
    
    
    
    
    
    
    
    
    
    
    3,102
    
    
    
    210,090Total operating expenses
    
    
    14,800,353
    
    
    
    7,605,059
    
    
    
    22,808,699
    
    
    
    15,445,239LOSS FROM OPERATIONS
    
    
    (14,155,620
    )
    
    
    (6,749,222
    )
    
    
    (21,275,601
    )
    
    
    (13,079,757
    )Interest income
    
    
    125,147
    
    
    
    56,726
    
    
    
    246,979
    
    
    
    112,268Interest expense
    
    
    (25,324
    )
    
    
    (9,719
    )
    
    
    (46,945
    )
    
    
    (20,527
    )Other income (expense), net
    
    
    4,850
    
    
    
    11,722
    
    
    
    (62,071
    )
    
    
    19,369LOSS BEFORE INCOME TAXES
    
    
    (14,050,947
    )
    
    
    (6,690,493
    )
    
    
    (21,137,638
    )
    
    
    (12,968,647
    )Provision for income taxes
    
    
    
    
    
    
    (62
    )
    
    

    (1,898
    )
    
    
    (2,120
    )NET LOSS
    
    $
    (14,050,947
    )
    
    $
    (6,690,555
    )
    
    $
    (21,139,536
    )
    
    $
    (12,970,767
    )NET LOSS PER SHARE:BASIC AND DILUTED
    
    $
    (0.14
    )
    
    $
    (0.09
    )
    
    $
    (0.22
    )
    
    $
    (0.18
    )WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING:BASIC AND DILUTED
    
    
    98,262,726
    
    
    
    71,285,690
    
    
    
    97,044,095
    
    
    
    71,248,769
 See notes to consolidated financial statements. 5




---



##### Table of Contents



AVANIR Pharmaceuticals 
 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) 
 Six Months Ended March 31,2005
    
    
    2004OPERATING ACTIVITIES:Net loss
    
    $
    (21,139,536
    )
    
    $
    (12,970,767
    )Adjustments to reconcile net loss to net cash used for
operating activities:Depreciation and amortization
    
    
    913,363
    
    
    
    794,261Compensation
paid with stock options
    
    
    5,402
    
    
    
    29,471Issuance of
common stock in connection with acquisition of additional contractual
rights to Neurodex (Note 11)
    
    
    5,300,000
    
    
    
    Other-than-temporary impairment of investment
    
    
    78,012
    
    
    
    Loss on disposal of assets
    
    
    2,827
    
    
    
    Intangible assets abandoned
    
    
    177,965
    
    
    
    Changes in assets and liabilities:Receivables
    
    
    (81,118
    )
    
    
    92,781Inventory
    
    
    3,102
    
    
    
    198,450Prepaid expenses and other assets
    
    
    (611,219
    )
    
    
    380,440Accounts payable
    
    
    (222,366
    )
    
    
    116,215Accrued expenses and other liabilities
    
    
    1,338,685
    
    
    
    1,239,328Accrued compensation and payroll taxes
    
    
    90,531
    
    
    
    71,627Deferred revenue
    
    
    (1,028,145
    )
    
    
    (1,080,505
    )Net cash used for operating activities
    
    
    (15,172,497
    )
    
    
    (11,128,699
    )INVESTING ACTIVITIES:Investments in securities
    
    
    (4,339,986
    )
    
    
    (997,112
    )Proceeds from sales and maturities of investments in securities
    
    
    7,914,365
    
    
    
    700,000Patent costs
    
    
    (551,777
    )
    
    
    (556,852
    )Purchases of property and equipment
    
    
    (239,568
    )
    
    
    (71,786
    )Net cash provided by (used for) investing activities.
    
    
    2,783,034
    
    
    
    (925,750
    )FINANCING ACTIVITIES:Proceeds from issuance of common stock and warrants, net
    
    
    7,196,498
    
    
    
    7,929,678Proceeds from issuance of notes payable
    
    
    136,438
    
    
    
    159,918Payments on notes and capital lease obligations
    
    
    (231,070
    )
    
    
    (323,062
    )Net cash provided by financing activities
    
    
    7,101,866
    
    
    
    7,766,534Net decrease in cash and cash equivalents
    
    
    (5,287,597
    )
    
    
    (4,287,915
    )Cash and cash equivalents at beginning of period
    
    
    13,494,083
    
    
    
    12,198,408Cash and cash equivalents at end of period
    
    $
    8,206,486
    
    
    $
    7,910,493SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:Interest paid
    
    $
    46,945
    
    
    $
    20,527Income taxes paid
    
    $
    1,898
    
    
    $
    2,120
 See notes to consolidated financial statements. 6




---



##### Table of Contents



AVANIR Pharmaceuticals 
 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 
 1. BASIS OF PRESENTATION AvanirPharmaceuticals (Avanir, we, or the Company) has prepared the
unaudited condensed consolidated financial statements in this quarterly report in accordance with
the instructions to Form 10-Q adopted under the Securities Exchange Act of 1934. Certain
information and note disclosures normally included in consolidated financial statements prepared in
accordance with accounting principles generally accepted in the United States have been condensed
or omitted pursuant to such rules and regulations. These unaudited condensed consolidated
financial statements should be read with our audited consolidated financial statements and the
accompanying notes included in our Annual Report on Form 10-K for the fiscal year ended September
30, 2004. In the opinion of management, all adjustments (consisting only of normal recurring
adjustments) necessary to present a fair statement of our financial position as of March 31, 2005
and September 30, 2004, and the results of operations for the three-month and six-month periods
ended March 31, 2005 and 2004, have been made. Operating results for the interim periods are not
necessarily indicative of operating results for the entire fiscal year. The preparation of financial statements in conformity with accounting principles generally accepted
in the United States requires management to make estimates and assumptions that affect the reported
amounts and the disclosure of contingent amounts in the financial statements and accompanying
notes. Actual results could differ from those estimates. Certain prior year amounts have been
reclassified to conform to the current year presentation. The unaudited condensed consolidated financial statements include the accounts of Avanir
Pharmaceuticals and its wholly-owned subsidiaries, Xenerex Biosciences and Avanir Holding Company.
All intercompany accounts and transactions have been eliminated. 2. STOCK-BASED COMPENSATION In December 2004, the Financial Accounting Standards Board (FASB) revised Statement of Financial
Accounting Standards No. 123 (FAS 123R), Share-Based Payment. FAS 123R will require us to
measure the cost of all employee stock-based compensation awards based on the grant date fair value
of those awards and to record that cost as compensation expense over the period during which the
employee is required to perform service in exchange for the award (generally over the vesting
period of the award). Excess tax benefits, as defined by FAS 123R, will be recognized as an
addition to common stock. On April 14, 2005, the U.S. Securities and Exchange Commission
(SEC) adopted a new rule amending the compliance dates for FAS 123R. In accordance with the new
rule, the accounting provisions of FAS 123R will be effective for us in the fiscal year starting
October 1, 2005. We are currently evaluating the effect of this
pronouncement on our financial condition and results of operations. Until FAS 123R becomes effective, we have chosen to continue to account for stock-based
compensation using the intrinsic value method prescribed in APB Opinion No. 25, and related
interpretations for all periods presented. Accordingly, compensation
costs for stock options granted to employees are
measured as the excess, if any, of the fair value of our common stock at the date of the grant over
the amount the employee must pay to acquire the stock. The following table summarizes the impact on our net loss had compensation costs been determined
based upon the fair value at the grant date for awards under the stock option plans consistent with
the methodology prescribed under FAS 123. 7




---



##### Table of Contents



Three Months Ended
    
    
    Six Months EndedMarch 31,
    
    
    March 31,2005
    
    
    2004
    
    
    2005
    
    
    2004Net loss, as reported
    
    $
    (14,050,947
    )
    
    $
    (6,690,555
    )
    
    $
    (21,139,536
    )
    
    $
    (12,970,767
    )Add: Stock-based
employee compensation expense
    
    
    
    
    
    
    12,227
    
    
    
    
    
    
    
    24,069Deduct: Total
stock-based employee
compensation expense determined under fair value based method for all
awards
    
    
    (453,794
    )
    
    
    (274,054
    )
    
    
    (732,457
    )
    
    
    (576,106
    )Pro forma net loss
    
    $
    (14,504,741
    )
    
    $
    (6,952,382
    )
    
    $
    (21,871,993
    )
    
    $
    (13,522,804
    )Net loss per share:Basic and diluted -
as reported
    
    $
    (0.14
    )
    
    $
    (0.09
    )
    
    $
    (0.22
    )
    
    $
    (0.18
    )Basic and diluted -
pro forma
    
    $
    (0.15
    )
    
    $
    (0.10
    )
    
    $
    (0.23
    )
    
    $
    (0.19
    )
 We account for stock options granted to non-employees in accordance with Emerging Issues Task
Force No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for
Acquiring, or in Conjunction with Selling, Goods or Services, (EITF 96-18). Under EITF 96-18,
we determine the fair value of the stock options granted as either the fair value of the
consideration received or the fair value of the equity instruments issued, whichever is more
reliably measurable. For the purpose of determining compensation expense for stock options granted
to non-employees, all of our directors are considered to be employees. 3. BALANCE SHEET DETAILS The following tables provide details of selected balance sheet items. Receivables, net.Receivables as of March 31, 2005 and September 30, 2004 consist of the following: March 31,
    
    
    September 30,2005
    
    
    2004Total receivables
    
    $
    338,497
    
    
    $
    257,379Allowance for doubtful accounts
    
    
    (17,500
    )
    
    
    (17,500
    )Receivables, net
    
    $
    320,997
    
    
    $
    239,879
 Property and equipment, net.Property and equipment consist of the following: 8




---



##### Table of Contents



March 31, 2005
    
    
    September 30, 2004Gross
    
    
    
    
    
    
    
    
    
    
    GrossCarrying
    
    
    Accumulated
    
    
    
    
    
    
    Carrying
    
    
    AccumulatedValue
    
    
    Depreciation
    
    
    Net
    
    
    Value
    
    
    Depreciation
    
    
    NetResearch and
development
equipment
    
    $
    3,763,401
    
    
    $
    (2,387,817
    )
    
    $
    1,375,584
    
    
    $
    3,701,461
    
    
    $
    (2,021,193
    )
    
    $
    1,680,268Computer equipment
and related
software
    
    
    1,081,775
    
    
    
    (621,579
    )
    
    
    460,196
    
    
    
    999,073
    
    
    
    (545,953
    )
    
    
    453,120Leasehold
improvements
    
    
    5,034,679
    
    
    
    (1,349,839
    )
    
    
    3,684,840
    
    
    
    5,032,605
    
    
    
    (1,048,184
    )
    
    
    3,984,421Construction in
progress
    
    
    29,440
    
    
    
    
    
    
    
    29,440
    
    
    
    
    
    
    
    
    
    
    
    Office equipment,
furniture, and
fixtures
    
    
    607,229
    
    
    
    (331,279
    )
    
    
    275,950
    
    
    
    558,970
    
    
    
    (285,815
    )
    
    
    273,155Total property
and equipment
    
    $
    10,516,524
    
    
    $
    (4,690,514
    )
    
    $
    5,826,010
    
    
    $
    10,292,109
    
    
    $
    (3,901,145
    )
    
    $
    6,390,964
 Depreciation expense related to property and equipment for the three-month and six-month
periods ended March 31, 2005 was approximately $384,000 and $802,000, respectively, as compared to
$381,000 and $757,000 for the three-month and six-month periods ended March 31, 2004, respectively. Intangible assets.We account for intangible assets in accordance with Statement of Financial
Accounting Standards No. 142, Goodwill and Other Intangible
Assets (FAS 142). In accordance with FAS 142, goodwill and other intangible assets that have
indefinite useful lives are not amortized; however, these assets must be reviewed at least
annually for impairment. Intangible assets with finite lives are to be
amortized over their useful lives and are evaluated for impairment whenever events or changes in
circumstances indicate that their carrying value may not be
recoverable under FAS No. 144, Accounting
for Impairment or Disposal of Long-lived Assets. If the review indicates that long-lived assets
are not recoverable (i.e. the carrying amount is less than the future projected undiscounted cash
flows), then their carrying value would be reduced to fair value. Intangible
assets with indefinite useful lives consist of costs of trademarks
for AVANIRTM and XenerexTM and similar names
intended for use or potential use in the United States and the rest
of the world. Intangible
assets with finite useful lives consist of capitalized legal costs incurred in connection with patents, patent applications pending,
trademark applications and license agreements. We amortize costs of approved patents, patent
applications pending, and license agreements over their useful lives, or terms of the agreements,
whichever are shorter. For patents pending, we amortize the costs over the shorter of a period of
twenty years from the date of filing the application or, if licensed, the term of the license
agreement. We re-assess the useful lives of patents when they are issued, or whenever events or
changes in circumstances indicate the useful lives may have changed. For patent and trademark
applications that we abandon, we charge the remaining unamortized accumulated costs to research and
development expense. Our amortizable intangible assets consist of the costs of patents, patent
applications and licenses. Intangible assets, consisting of both intangible assets with finite and indefinite useful lives as
of March 31, 2005 and September 30, 2004, are as follows: 9




---



##### Table of Contents



March 31, 2005
    
    
    September 30, 2004Gross
    
    
    
    
    
    
    
    
    
    
    GrossCarrying
    
    
    Accumulated
    
    
    
    
    
    
    Carrying
    
    
    AccumulatedValue
    
    
    Depreciation
    
    
    Net
    
    
    Value
    
    
    Depreciation
    
    
    NetIntangible assets with
finite lives:Patent applications
pending (1)
    
    $
    2,717,836
    
    
    $
    (204,829
    )
    
    $
    2,513,007
    
    
    $
    2,462,704
    
    
    $
    (166,000
    )
    
    $
    2,296,704Patents
    
    
    1,110,061
    
    
    
    (379,258
    )
    
    
    730,803
    
    
    
    1,010,097
    
    
    
    (339,552
    )
    
    
    670,545Licenses
    
    
    42,461
    
    
    
    (16,775
    )
    
    
    25,686
    
    
    
    42,461
    
    
    
    (15,647
    )
    
    
    26,814Total intangible
assets with finite
lives
    
    
    3,870,358
    
    
    
    (600,862
    )
    
    
    3,269,496
    
    
    
    3,515,262
    
    
    
    (521,199
    )
    
    
    2,994,063Intangible assets with
indefinite useful
lives (2)
    
    
    37,608
    
    
    
    
    
    
    
    37,608
    
    
    
    40,961
    
    
    
    
    
    
    
    40,961Total intangible assets
    
    $
    3,907,966
    
    
    $
    (600,862
    )
    
    $
    3,307,104
    
    
    $
    3,556,223
    
    
    $
    (521,199
    )
    
    $
    3,035,024
   (1)
    
    Patent applications pending includes the net effect of $2,944 and $173,272 (net of
accumulated amortization of $68 and $18,389) in intangible assets abandoned during the
three-month and six-month periods ended March 31, 2005,
respectively. We abandoned certain therapeutic use patents pending in
selected countries
related to potential treatments of allergy and asthma, and cancer,
because we were able to obtain superior claims in composition-of-matter patents.(2)
    
    Intangible assets with indefinite useful lives includes the net effect of $4,693 in
trademarks abandoned during the three-month and six-month periods ended March 31, 2005. Amortization expense related to amortizable intangible assets for the three-month and
six-month periods ended March 31, 2005 was approximately $55,000 and $102,000, respectively, as
compared to $20,000 and $37,000 for the three-month and six-month periods ended March 31, 2004,
respectively. Based solely on the amortizable intangible assets as of March 31, 2005, the
estimated annual amortization expense of intangible assets for the fiscal years ending September 30
is shown in the following table. Actual amortization expense to be reported in future periods
could differ from these estimates as a result of acquisitions, divestitures, and other relevant
factors. Amortization Expense Fiscal year ending September 30:2005 (remaining six months)
    
    $
    110,0002006
    
    
    218,0002007
    
    
    218,0002008
    
    
    218,0002009
    
    
    210,000Thereafter
    
    
    2,295,000Total
    
    $
    3,269,000
 4. INVENTORY Inventory is stated at the lower of cost (first-in, first-out) or market. Inventory consists of
the raw material docosanol, which is the active pharmaceutical ingredient in docosanol 10% cream.
Docosanol in its present form as stored by us has a substantial shelf life, a relatively stable
value and long-term use, and carries a low risk of becoming excess inventory or obsolete. We do
not own or store any docosanol 10% cream in its finished product form. We and one of our licensees
receive raw materials from a single supplier. We also supply several other licensees with raw
materials from the same supplier. The inability of a sole supplier to fulfill our or our
licensees supply requirements could materially impact future operating results. 5. DEFERRED REVENUE We have license agreements with additional or continuing obligations to perform under the
agreements. In such arrangements, certain revenues have been deferred until the performance
obligations have been met or ratably achieved (see also Note 6,
Revenue Recognition). In December 2002, we sold to Drug Royalty USA, Inc.
(Drug Royalty USA) an undivided interest in our rights to receive future Abreva® royalties under
the license agreement with GlaxoSmithKline subsidiary, SB Pharmco Puerto Rico (SB), for $24.1
million (the Drug Royalty USA Agreement and SB License Agreement, respectively). Under the
Drug Royalty USA Agreement, 10




---



##### Table of Contents



Drug Royalty USA has the right to receive royalties from SB on sales of
Abreva until the later of December 2013 or the date of expiration of a certain Abreva patent in
accordance with the SB License Agreement. The terms of the Drug Royalty USA Agreement contain certain covenants under which we must perform
in order to satisfy the continuing terms and conditions of the arrangement. In certain
circumstances, nonperformance on our part could result in default of the arrangement, and could
trigger a separate security agreement with Drug Royalty USA, which could result in loss of our
rights to share in future Abreva® royalties if wholesale sales
exceed $62 million in a year. The
nature of these terms and covenants results in our continuing involvement and, accordingly, we
recorded the net proceeds of the transaction as deferred revenue, to be recognized as revenue
ratably over the expected life of the license agreement. The following table sets forth as of March 31, 2005 the deferred revenue balances for the Drug
Royalty USA Agreement and other agreements. The portion of deferred revenue classified as a
current liability represents the amount Avanir expects to realize as revenue within the
next 12 months. Drug Royalty
    
    
    OtherUSA Agreement
    
    
    Agreements
    
    
    TotalDeferred revenue as of September 30, 2004
    
    $
    20,800,782
    
    
    $
    208,333
    
    
    $
    21,009,115Changes during the period:Recognized as revenue during period
    
    
    (928,145
    )
    
    
    (100,000
    )
    
    
    (1,028,145
    )Deferred revenue as of March 31, 2005
    
    $
    19,872,637
    
    
    $
    108,333
    
    
    $
    19,980,970Classified as:Current portion of deferred revenue
    
    $
    1,899,561
    
    
    $
    33,333
    
    
    $
    1,932,894Deferred revenue, net of current portion
    
    
    17,973,076
    
    
    
    75,000
    
    
    
    18,048,076Total deferred revenue
    
    $
    19,872,637
    
    
    $
    108,333
    
    
    $
    19,980,970
 6. REVENUE RECOGNITION Performance-based license fees.We recognize revenues from license fees when the performance
requirements have been met, the fee is fixed or determinable, and collection of fees is probable.
We defer revenues and recognize them ratably over the life of the agreement when we have continuing
obligations to perform under the agreement. Royalty revenues.We recognize royalty revenues from licensed products when earned in accordance
with the terms of the license agreements and reported by the licensees. Net sales figures used for
calculating royalties can often include deductions for costs of unsaleable returns, managed care
chargebacks, cash discounts, freight and warehousing, and miscellaneous write-offs, which may vary
over the course of the license agreement. Revenues from sale of royalty rights.In agreements where we have sold our rights to future
royalties under license agreements and we maintain continuing involvement in earning such
royalties, we defer revenues and recognize them over the life of the license agreement. For
example, in the sale of an undivided interest of our Abreva license agreement to Drug Royalty USA,
revenue recognition is being
determined under the units-of-revenue method. Under this method, the amount of deferred revenue to
be recognized as revenue in each period is calculated by multiplying (i) the ratio of the royalty
payments due to Drug Royalty USA for the period to the total remaining royalties that we expect SB
will pay Drug Royalty USA over the term of the agreement, by (ii) the unamortized deferred revenue
amount. Revenue arrangements with multiple deliverables.We have revenue arrangements whereby we are
obligated to deliver to the customer multiple products and/or services (multiple deliverables).
Such 11




---



##### Table of Contents



arrangements could include antibody generation services agreements and other forms of research
collaborations. In these transactions, we allocate the total revenue to be earned under the
arrangement among the various elements based on their relative fair value. In the case of antibody
generation services, the allocation is based on objective, customer-specific evidence of fair
value. We recognize revenue related to the delivered products or services only if: (i) the above
performance or service criteria are met; (ii) any undelivered products or services are not
essential to the functionality of the delivered products or services; (iii) payment for the
delivered products or services is not contingent upon delivery of the remaining products or
services; (iv) we have an enforceable claim to receive the amount due in the event we do not
deliver the undelivered products or services; and (v) as discussed above, there is evidence of the
fair value for each of the undelivered products or services. Government research grant revenue.We recognize revenues from federal research grants during the
period in which the related expenditures are incurred. Product sales  Active Pharmaceutical Ingredient Docosanol.Revenue from product sales, which
consist of sales of our active pharmaceutical ingredient
docosanol, is recorded when the
following criteria are met: there is written evidence that an arrangement exists; products are
shipped and title and risk of loss have passed to the buyer upon delivery; the price to the buyer
is fixed and determinable; and collectibility is reasonably assured. We sell the active
pharmaceutical ingredient docosanol to various licensees and ship only on written order for the
materials. Our total shipments occur fewer than five times a year. Our contracts for sales of the
active pharmaceutical ingredient docosanol include buyer acceptance provisions that give our buyers the right
of replacement if the delivered materials do not meet specified criteria, by giving notice within
30 days after receipt of such defective materials, and we have the option to refund or replace such
defective materials. However, we have historically demonstrated that the materials shipped from
the same pre-inspected lot have consistently met the specified criteria and no buyer has rejected
any of our shipments from the same pre-inspected lot. Therefore, we recognize revenue from sales
of the active pharmaceutical ingredient docosanol without providing for such contingency upon
shipment. 7. INVESTMENTS Investments are comprised of marketable securities consisting primarily of certificates of deposit,
federal, state and municipal government obligations, and corporate
bonds. All marketable
securities are held in our name and primarily under the custodianship of two major financial
institutions. Our policy is to protect the principal value of our investment portfolio and minimize
principal risk by earning returns based on current interest rates. Short-term investments are
marketable securities with maturities of less than one year from the balance sheet date. Statement of Financial Accounting Standards No. 115 (FAS 115), Accounting for Certain Investments
in Debt and Equity Securities, addresses the accounting and reporting for investments in equity
securities that have readily determinable fair values and for all investments in debt securities.
Those investments are to be classified in three categories and accounted for as follows:  
    Debt securities that we have the positive intent and ability to hold to maturity are
classified as held-to-maturity securitiesand reported at amortized cost.
    Debt and equity securities that are bought and held principally for the purpose of
selling them in the near term are classified as trading securitiesand reported at fair
value, with unrealized gains and losses included in our Consolidated Statement of
Operations.
    Debt and equity securities not classified as either held-to-maturity securities or
trading securities are classified as available-for-sale securitiesand reported at fair
value, with unrealized gains and losses excluded from the Consolidated Statement of
Operations and reported in a separate component of shareholders equity. 12




---



##### Table of Contents



FAS 115 also requires companies to determine whether a decline in fair value below the amortized
cost basis is other-than-temporary. If a decline in fair value is determined to be
other-than-temporary, FAS 115 requires the carrying value of the debt or equity security to be
permanently written down to its fair value. In making an evaluation of whether or not an
investment is impaired, we applied the effective paragraphs of EITF 03-1, The Meaning of
Other-Than-Temporary Impairment and Its Application to Certain Investments. In evaluating whether
or not the impairment is other-than-temporary, we consider the duration and severity of the
impairment, as well as the intent and ability to hold the investment until recovery, among other
factors. The following tables summarize our investments in securities, all of which are classified as
available-for-sale except for restricted investments, which are classified as held-to-maturity. Gross
    
    
    GrossAmortized
    
    
    Unrealized
    
    
    Unrealized
    
    
    FairCost
    
    
    Gains (1)
    
    
    Losses (1)
    
    
    ValueAs of March 31, 2005:Certificates of deposit
    
    $
    956,597
    
    
    $
    564
    
    
    $
    
    
    
    $
    957,161Government debt securities
    
    
    7,887,832
    
    
    
    
    
    
    
    (85,467
    )
    
    
    7,802,365Total
    
    $
    8,844,429
    
    
    $
    564
    
    
    $
    (85,467
    )
    
    $
    8,759,526Reported as:Short term investments:Classified as available-for-sale
    
    $
    5,050,680Long term investments:Classified as available-for-sale
    
    
    2,852,249Restricted investments in
securities (3)
    
    
    856,597Long-term investments
    
    
    3,708,846Total
    
    $
    8,759,526
 Gross
    
    
    GrossAmortized
    
    
    Unrealized
    
    
    Unrealized
    
    
    FairCost
    
    
    Gains (4)
    
    
    Losses (4)
    
    
    ValueAs of September 30, 2004:Certificates of deposit
    
    $
    1,356,597
    
    
    $
    3,558
    
    
    $
    
    
    
    $
    1,360,155Adjustable rate mutual fund (2)
    
    
    3,014,365
    
    
    
    
    
    
    
    (68,650
    )
    
    
    2,945,715Government debt securities
    
    
    8,125,858
    
    
    
    6,186
    
    
    
    (25,468
    )
    
    
    8,106,576Total
    
    $
    12,496,820
    
    
    $
    9,744
    
    
    $
    (94,118
    )
    
    $
    12,412,446Reported as:Short term investments:Classified as available-for-sale
    
    $
    8,803,982Long term investments:Classified as available-for-sale
    
    
    2,751,867Restricted investments in
securities (3)
    
    
    856,597Long-term investments
    
    
    3,608,464Total
    
    $
    12,412,446
   (1)
    
    Gross unrealized gains of $564 on certificates of deposit and gross unrealized losses of
$85,467 on government debt securities represent an accumulated net unrealized loss of $84,903,
which is reported as accumulated other comprehensive loss on the consolidated balance sheet
as of March 31, 2005.(2)
    
    Represents an investment in a mutual fund that invested primarily in adjustable rate
mortgage-backed securities. We sold the investment in February 2005.(3)
    
    Represents amounts pledged to our bank as collateral for letters of credit issued in
connection with our leases of office and laboratory space.(4)
    
    Gross unrealized gains of $9,744 and gross unrealized losses of $94,118 on government
securities, the adjustable rate mutual fund, and certificates of deposit represent an
accumulated net unrealized loss of $84,374, which is reported as accumulated other
comprehensive loss on the consolidated balance sheet as of September 30, 2004.   13




---



##### Table of Contents



8. COMPUTATION OF NET LOSS PER COMMON SHARE We compute basic net loss per common share by dividing the net loss by the weighted-average number
of common shares outstanding during the period (Basic EPS Method). We compute diluted net loss
per common share by dividing the net loss by the weighted-average number of common and dilutive
common equivalent shares outstanding during the period (Diluted EPS Method). Dilutive common
equivalent shares consist of shares issuable upon exercise of stock options and warrants. In the
accompanying consolidated statements of operations, we have presented our net loss per share for
the three-month and six-month periods ended March 31, 2005 and 2004 using the Basic EPS Method and
the Diluted EPS Method. The shares of common stock issuable upon exercise of stock options and
warrants under the Diluted EPS Method were excluded from the three-month and six-month periods
ended March 31, 2005 and 2004, as the inclusion of such shares would have been anti-dilutive. For the three-month and six-month periods ended March 31, 2005 and 2004, options to purchase
6,012,976 and 5,250,357 shares of common stock, respectively, were excluded from the computation of
diluted net loss per share, as the inclusion of such shares would be antidilutive. For the
three-month and six-month periods ended March 31, 2005 and 2004, warrants to purchase 5,245,261 and
5,442,911 shares of common stock, respectively, were excluded from the computation of diluted net
loss per share, as the inclusion of such shares would be antidilutive. 9. COMPREHENSIVE LOSS Comprehensive loss consists of the following: Three Months Ended
    
    
    Six Months EndedMarch 31,
    
    
    March 31,2005
    
    
    2004
    
    
    2005
    
    
    2004Net loss
    
    $
    (14,050,947
    )
    
    $
    (6,690,555
    )
    
    $
    (21,139,536
    )
    
    $
    (12,970,767
    )Other comprehensive
loss, net of tax:Unrealized gain
(loss) on
available-for-sale
securities
    
    
    (41,464
    )
    
    
    838
    
    
    
    (529
    )
    
    
    (30,761
    )Total comprehensive loss
    
    $
    (14,092,411
    )
    
    $
    (6,689,717
    )
    
    $
    (21,140,065
    )
    
    $
    (13,001,528
    )
 10. SHAREHOLDERS EQUITY Preferred stock.Preferred stock consists of Series C Junior Participating Preferred Stock, of
which none is outstanding. Class A common stock.In March 2005, we issued 2,000,000 shares of
Class A common stock, with a
fair value of $5.3 million, to IriSys, Inc. (IriSys) in connection with the acquisition of
contractual rights to Neurodex, our late-stage drug candidate for the treatment of multiple
central nervous system disorders.
We valued these shares at $2.65 per share, based on the 5-day average closing price of our common
stock, beginning two days before and ending two days after the close
and announcement of the agreement on March 9, 2005. See
Note 11, Related Party Transactions, for further discussions. In December 2004, we issued and sold to CDIB Capital Investment America Ltd., a wholly-owned
subsidiary of China Development Industrial Bank, Inc., 2,333,333 shares of Class A common stock at
a price of $3.00 per share, for aggregate offering proceeds of approximately $7 million. The
offering was made pursuant to our shelf registration statement on Form S-3, filed on April 9, 2004. During the three-month period ended March 31, 2005, we also issued an aggregate of 81,611 shares of
Class A common stock in connection with the exercise of stock purchase warrants (62,047 shares) and 14




---



##### Table of Contents



employee stock options (19,564 shares) for cash in the aggregate amount of approximately $156,517,
representing a weighted-average price per share of $1.92. 11. RELATED PARTY TRANSACTIONS On
August 1, 2000, we entered into an agreement with IriSys, Inc. (formerly IriSys Research and
Development, LLC) to sublicense the exclusive worldwide rights to a patented drug formulation,
Neurodex, to treat multiple central nervous system disorders (Sublicense Agreement). IriSys
held exclusive rights to Neurodex under an Exclusive Patent License Agreement with the Center for
Neurologic Study (CNS), dated April 2, 1997 (the License Agreement). Under the Sublicense
Agreement, we were obligated to make certain payments upon achieving
certain specified
milestones, royalties on product sales and a specified percentage of any future royalties that we might have
received from potential licensees. We had never made any payments nor
were any payments due to IriSys
under the Sublicense Agreement. On March 8, 2005, we entered into an Asset Purchase Agreement, pursuant to which our wholly owned
subsidiary, Avanir Holding Company, acquired from IriSys certain additional contractual rights to
Neurodex. As a result, through our wholly owned subsidiary we hold the exclusive worldwide
marketing rights to Neurodex for certain indications as set forth
under the License Agreement and have no further license arrangements
with IriSys.
We will be obligated to
pay CNS milestone payments upon achievement of certain future events relating to the FDAs
regulatory approval process for Neurodex and a royalty on commercial sales of Neurodex, if and when the drug is
approved by the FDA for commercialization. Under certain circumstances, we may have the obligation
to pay CNS a share of net revenues received if we sublicense Neurodex to a third party. As of the
date of this report, we have not triggered any of these milestone or royalty payments and, therefore, no
payment is due CNS. Pursuant
to the Asset Purchase Agreement, we paid IriSys a purchase price of $7,225,000
including $1,925,000 in cash and 2,000,000 shares of our Class A common stock with a fair value of
$5,300,000. The fair value of the common stock was calculated at $2.65 per share using the 5-day
average closing price of our common stock, beginning two days before and ending two days after the
close and announcement of the agreement on March 9, 2005.
Because of the uncertainty of receiving future economic benefits from the
acquired contractual rights,
particularly given that Neurodex has not been approved by the FDA for
commercialization, the purchase price was immediately charged to research and
development expense in accordance with United States generally
accepted accounting principles. Dr. Yakatan, our president and chief executive officer, is a founder and the majority shareholder
of IriSys. As required by the Asset Purchase Agreement, Dr. Yakatan resigned as a director of
IriSys effective April 9, 2005. Fair
Value Analysis. Standard & Poors Corporate Value
Consulting group (S&P) served as
the financial advisor to the Corporate Governance Committee, which
negotiated the contract on behalf of the Board and the Company. S&P reviewed the
terms of the Asset Purchase Agreement and provided the Committee with a favorable opinion
regarding the fairness, from a financial point of view, of the agreement to AVANIR and its
shareholders. In assessing the value or the assets acquired pursuant to the agreement, S&P considered various financial models for the
commercialization of Neurodex for different indications, as well as the projected discounted cash
flow and net present value under each such model. The
forecast and
discount rates used in the valuation models take into account  the stage of completion and the risks surrounding the
successful development and commercialization of each of the product candidates that were
valued. The resulting projected net cash flows were based on
estimated revenue, cost of sales, R&D costs, selling, general and administrative costs, and
income taxes for such projects that would be experienced by most
potential buyers and be similar to our cost structure. If
Neurodex is not successfully developed for each indication, our revenue and profitability may be adversely
affected in future periods. We
believe that the assumptions used in the valuation of the acquired contractual rights to Neurodex
represent a reasonably reliable estimate of the future benefits attributable to the acquired
contractual rights to Neurodex, assuming the FDA approves Neurodex
for both indications. No
assurance can be given that actual results will not deviate from those assumptions in future
periods. 12. RECENT ACCOUNTING PRONOUNCEMENTS In November 2004, the FASB issued Statement of Financial Accounting Standards No. 151 (FAS 151),
Inventory Costs, an Amendment of ARB No. 43, Chapter 4, that is effective for inventory costs
incurred during fiscal years beginning after June 15, 2005. FAS 151 requires that abnormal amounts
of idle facility expense, freight, handling costs and wasted material (spoilage), as well as
unallocated overhead, be recognized as current period charges. We do not expect FAS 151 to
significantly affect our financial condition or results of operations. 15




---



##### Table of Contents



In March 2005, the FASB issued Interpretation No. 47 (FIN 47), Accounting for Conditional Asset
Retirement Obligations. FIN 47 clarifies that an entity must record a liability for a conditional
asset retirement obligation if the fair value of the obligation can be reasonably estimated. The
provision is effective no later than the end of fiscal years ending
after December 15, 2005. We do not expect FIN 47 to
significantly affect our financial condition or results of operations. 13. COMMITMENTS AND CONTINGENCIES In the ordinary course of business, we may face various claims brought by third parties, including
claims relating to the safety or efficacy of our products. Any of these claims could subject us to
costly litigation and, while we generally believe that we have adequate insurance to cover many
different types of liabilities, our insurance carriers may deny coverage or our policy limits may
be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the
payment of any such awards could have a material adverse effect on our operations and financial
position. Additionally, any such claims, whether or not successful, could damage our reputation
and business. Management believes the outcome of currently identified claims and lawsuits will not
have a material adverse effect on our operations or financial position. 14. SEGMENT INFORMATION We operate in one segment, which is the business of discovery, development and commercialization of
novel therapeutics for chronic diseases. Our chief operating decision-makers review our operating
results on an aggregate basis and manage our operations as a single operating segment. We have
developed one commercial product, docosanol 10% cream, known as Abreva® in the United States, and
we have several other product candidates in various stages of development. We have licensed
docosanol 10% cream to other companies that market the product and provide us royalties on product
sales. 15. SUBSEQUENT EVENTS On April 8, 2005, we completed the sale of 7,770,000 shares of Class A common stock at a price of
$2.20 per share to certain investors, for aggregate proceeds of approximately $17.1 million,
resulting in net proceeds of approximately $15.8 million after deducting offering expenses and
commissions. The shares were offered under our effective shelf registration statement on Form S-3
filed in April 2004 and amended in April 2005. On April 27, 2005, we entered into a research, development and commercialization agreement with
Novartis International Pharmaceutical Ltd. (Novartis) to develop orally active small molecule
therapeutics targeting macrophage migration inhibitory factor as a potential treatment for
inflammatory diseases. Under the terms of the agreement, we are eligible to receive over $200
million in milestone and
royalty payments upon the achievement of certain predetermined development, regulatory and sales
objectives. Under this agreement, we received a payment of
$2.5 million on May 6, 2005 and
will also receive annual research funding of between
$1.5 million and $2.5 million for up to four
years of the agreement. Novartis will assume all responsibility for product development expenses
and both parties will contribute expertise and intellectual property. 16




---



##### Table of Contents



Item 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Quarterly Report on Form 10-Q contains forward-looking statements concerning future events and
performance of our company. When used in this report, the words intend, estimate,
anticipate, believe, plan or expect and similar expressions are included to identify
forward-looking statements. These forward-looking statements are based on our current expectations
and assumptions and many factors could cause our actual results to differ materially from those
indicated in these forward-looking statements. You should review carefully the factors identified
in this report under the caption, Risk Factors that Might Affect Future Operations and in our
most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. We
disclaim any obligation to update or announce revisions to any forward-looking statements to
reflect actual events or developments. Except as otherwise indicated herein, all dates referred to
in this report represent periods or dates fixed with reference to the calendar year, rather than
our fiscal year ending September 30. The three-month and six-month periods ended March 31, 2005,
may also be referred to as the second quarter and first half, respectively, of fiscal 2005. EXECUTIVE OVERVIEW Avanir Pharmaceuticals is a drug discovery and development company focused on
developing and commercializing novel treatments for chronic diseases. Avanir is currently developing Neurodex for the
treatment of pseudobulbar affect (PBA) and for the treatment of chronic diabetic neuropathic
pain. We have successfully completed two Phase III trials of Neurodex in the treatment of PBA and
one Phase II trial for the treatment of diabetic neuropathic pain. We also have a potential
product for allergy and asthma, AVP-13358, which is in Phase I clinical development. Our clinical and preclinical research and drug discovery programs are focused primarily on small
molecules that can be taken orally as therapeutic treatments. Other small molecule programs
include potential treatments for atherosclerosis and inflammation, which are both in the
preclinical development stage. Using our proprietary Xenerex technology, we are also conducting
research to develop injectable human monoclonal antibody products for anthrax, cytomegalovirus, and
other infectious diseases. 17




---



##### Table of Contents



The following chart illustrates the approximate status of research activities for our products and
product candidates that are under development. (FLOW CHART)   (a)
    Timelines in this pictorial representation are not to scale.(b)
    Investigational New Drug(c)
    New Drug Application for PBA is being submitted on a rolling basis (described further
in Research and Development Expenses). We strive to maintain a lean
organizational structure while working on a diverse product development pipeline. We also strive
to maintain flexibility in our cost structure, by actively managing outsourced functions such as
clinical trials, market research, legal counsel, documentation and testing of internal controls,
and portions of chemistry, rather than maintain all of these functions in house. While outsourcing
can lead to higher costs in some cases, we believe the benefits of being flexible, and being able
to rapidly respond to program delays, or successes, and the availability of capital to advance our
programs, far outweigh the disadvantages. We
are currently in the process of completing our rolling submission to
the U.S. Food and Drug Administration (FDA) of our New Drug
Application (NDA) for Neurodex for the treatment of PBA. We expect to complete that submission
in mid-2005. If Neurodex is approved by the FDA, we will market the product directly through a
dedicated contract sales organization starting in the first half of
2006. We are in the process of transforming from a research and development organization
into a commercially viable pharmaceutical company. In order to
facilitate that transformation, we
are investing in our infrastructure to support the planned commercial launch of Neurodex if
approved by the FDA. In preparation for the
commercial launch of Neurodex, we are in the process of selecting a contract sales
organization and are recruiting senior level sales and marketing personnel. We continue to evaluate co-promotion
alternatives for Neurodex. The goals of a co-promotion arrangement
will be to reach a broader target audience of physicians as well as
offset some of the development expenses associated with the
neuropathic pain indication. On March 8, 2005, we entered into an Asset Purchase Agreement, pursuant to which our wholly owned
subsidiary, Avanir Holding Company, acquired from IriSys, Inc. certain additional contractual rights
to Neurodex. As a result, through our subsidiary we hold the exclusive worldwide marketing rights
to Neurodex for five indications under a royalty-bearing license with the owner of the underlying
technology, The Center for Neurologic Study. Going forward, we will be obligated, if we achieve
certain
contingent events, to pay CNS milestones, a patent royalty on product sales, and a share of
revenues received if we sublicense Neurodex to a third party. We will have no future financial
obligation to 18




---



##### Table of Contents



IriSys.
In the transaction, IriSys was paid $1,925,000 in cash and received
2,000,000 shares of our Class A common stock, having a fair value of $5.3 million. On April 27, 2005, we entered into a research, development and commercialization agreement with
Novartis to develop orally active small molecule therapeutics targeting macrophage migration
inhibitory factor (MIF) as a potential treatment for inflammatory diseases. Under the terms of
the agreement, we are eligible to receive over $200 million in
milestone and royalty payments upon
the achievement of certain predetermined development, regulatory and sales objectives. Under this
agreement, we will also receive annual research funding of between
$1.5 million and $2.5 million for up
to four years of the agreement. Novartis will assume all responsibility for product development
expenses and both parties will contribute expertise and intellectual property. We intend to continue to seek partnerships with pharmaceutical companies to help fund other
research and development programs in exchange for sharing in the rights to commercialize new drugs.
We have licensed certain rights to docosanol 10% cream and our MIF development program, and we
continue to seek licensees for other potential products in our pipeline. We may also
seek to develop our drug candidates through research collaborations with larger pharmaceutical
companies, potentially allowing us to share the risks and the opportunities that come from such
development efforts. We expect that our development and operational costs will continue to exceed revenues from existing
sources through at least fiscal 2006. Trends in revenues and various types of expenses are
discussed further in the Results of Operations. We will have to raise significant amounts of
additional capital to prepare for and potentially
execute a product launch of Neurodex for PBA, if approved by the U.S. Food and Drug Administration
for marketing, and fund selected research and other operating activities. Our future capital needs will depend
substantially on the economic terms and the timing of any new partnership or collaborative
arrangements with pharmaceutical companies under which they will share the costs of such
activities. If we are unable to raise capital as needed to fund our operations, or if we are
unable to enter into any such collaborative arrangements, then we may need to slow the rate of
development of some of our programs or sell the rights to one or more
of our drug candidates, and our commercialization plans for Neurodex
may be adversely affected. For
additional information about the risks and uncertainties that may affect our business and
prospects, please see Risk Factors that Might Affect Future Operations. Our offices and research facilities are located at 11388 Sorrento Valley Road, San Diego,
California 92121. Our telephone number is (858) 622-5200 and our e-mail address is
info@avanir.com. Additional information about Avanir can be found on our website, at
www.avanir.com, and in our periodic and current reports filed with the Securities and Exchange
Commission (SEC). Copies of our current and periodic reports filed with the SEC are available at
the SEC Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549, and online at
www.sec.govand our website at www.avanir.com. RESULTS OF OPERATIONS COMPARISON OF THREE MONTHS ENDED MARCH 31, 2005 AND 2004 Revenues Revenues
for the second quarter of fiscal 2005 amounted to $645,000, including $420,000 from the
recognition of deferred revenue relating to the sale of an undivided interest in our Abreva®
license agreement to Drug Royalty USA (See Note 5, Deferred Revenue, in the Notes to Condensed
Consolidated Financial Statements (Unaudited)), $100,000 from
research contracts and licenses and $125,000 from government research grants.
Revenues from government research grants included preclinical research on a potential antibody to
anthrax ($100,000) and preclinical development of docosanol as a potential treatment for genital
herpes ($25,000). Revenues for the second quarter of fiscal 2004 amounted to $856,000, including
$268,000 from research contracts and licenses, $345,000 from the recognition of deferred revenue
relating to the 19




---



##### Table of Contents



sale of an undivided interest in our Abreva® license agreement, and $241,000 from
government research grants. During fiscal 2005, we expect to recognize approximately $1.9 million in revenues from the
recognition of deferred revenue relating to the sale of an undivided interest in our Abreva license
agreement, approximately $1.0 million in revenues from the
Novartis agreement, and $500,000 in revenues from research being performed under government research grants.
We expect sales of the active ingredient docosanol will be less than $100,000 in fiscal 2005.
Projected fiscal 2005 revenues from new sources, such as license fees and milestone payments from
Novartis and potentially other collaborative partners, will depend substantially on our ability to
enter into additional license arrangements and achieve milestones under those arrangements. Such
arrangements could be in the form of licensing or partnering agreements for docosanol 10% cream,
Neurodex, or for our other product development programs including potential treatments for PBA,
allergy and asthma, and atherosclerosis. Many of our product development programs could take years
of additional development before they reach the stage of licensing, if ever, by other
pharmaceutical companies. Revenue-generating Contracts Commercial contracts that remained active at the end of the second quarter of fiscal 2005 include
seven docosanol 10% cream license agreements and one Neurodex sublicense. The Abreva license
arrangement has been our most significant commercial revenue source during the past four years, accounting for
a majority of revenues in each of those years. Expenses Operating expenses.Total operating expenses for the second quarter of fiscal 2005 were $14.8
million, compared to $7.6 million in the same period in fiscal 2004. The increase of $7.2 million
or 95% in operating expenses was primarily caused by a $6.0 million increase in research and
development expenses, a $467,000 increase in general and administrative expenses and a $676,000
increase in sales and marketing expenses. These and other costs and trends are more fully
described below. Three Months Ended
    
    
    Six Months EndedMarch 31
    
    
    March 312005
    
    
    2004
    
    
    2005
    
    
    2004Operating expenses:Research and development
    
    
    77
    %
    
    
    71
    %
    
    
    72
    %
    
    
    70
    %General and administrative
    
    
    13
    %
    
    
    20
    %
    
    
    17
    %
    
    
    19
    %Sales and marketing
    
    
    10
    %
    
    
    9
    %
    
    
    11
    %
    
    
    10
    %Costs of sales
    
    
    
    %
    
    
    
    %
    
    
    
    %
    
    
    1
    %Total operating expenses
    
    
    100
    %
    
    
    100
    %
    
    
    100
    %
    
    
    100
    %
 Research and development (R&D) expenses.
R&D expenses for the second quarter of fiscal 2005 were
$11.4 million, compared to $5.4 million in the same period in fiscal
2004. The net increase of $6.0 million or
111% is attributable to the $7.2 million charge related to the acquisition of additional
contractual rights to Neurodex. The $7.2 million charge included $1,925,000 in cash and 2,000,000 shares of our Class A common stock with a fair value of $5.3 million. (See Note 11, Related Party Transactions,
in Notes to Condensed Consolidated Financial Statements (Unaudited).)
R&D expenses for the second
quarter of fiscal 2005 also included an $800,000 decrease in clinical spending on Neurodex for the treatment
of PBA, compared with the same period a year ago, as the program nears completion. Because of the uncertainty of receiving future economic benefits from the acquired contractual rights to
Neurodex, particularly given that the drug candidate has not been
approved by the FDA for commercialization, the $7.2 million fair
value of the acquired contractual rights to Neurodex was immediately expensed. We allocated 80%, or $5.8
million, of the purchase price to our product candidate for the treatment of PBA and 20%, or $1.4 million,
to our product candidate for the treatment of neuropathic pain, based on a fair value analysis conducted by
Standard & Poors Corporate Value Consulting group, as more fully described in Note 11. We plan to use
existing cash to develop Neurodex in the treatment of PBA and neuropathic pain, and estimated costs to
complete each of these projects is included in the table on R&D spending that follows. The open label study and costs
associated with preparing additional clinical data modules for submission of the NDA to
the FDA for Neurodex in the treatment of PBA in the second quarter of fiscal 2005 accounted for
approximately $1.6 million, compared to $2.4 million in the second quarter of fiscal 2004. We expect that
clinical spending on Neurodex for the treatment of PBA will continue to decline in future quarters in
2005 as the program nears completion. We expect to spend approximately $ 8.5 million in the next two-year
period  for a Phase III clinical trial of Neurodex for diabetic
neuropathic pain. The balance of R&D spending in the second quarter of fiscal 2005 was primarily for
preclinical research related to the development of compounds for the treatment of atherosclerosis, allergy
and asthma, inflammation and antibody research programs. 20




---



##### Table of Contents



We
expect R&D spending levels for neuropathic
pain, atherosclerosis and inflammation will increase in the coming quarters, as we expand and
advance those programs in the development pipeline. We expect that
spending on allergy and asthma and monoclonal antibodies will depend
in part on our success in partnering these programs so that we are
able to defray part or all of the ongoing development costs. Pharmaceutical R&D programs, by their very nature, require a substantial amount of financial and
human resources and there is no assurance that any drug candidate will be approved for marketing by
domestic and/or foreign regulatory agencies. The later stages of clinical development typically
require substantially greater funds for development than the earlier stages. Thus, for many of our
larger development programs such as atherosclerosis and allergy and asthma, we intend to license our technology or partner with other
pharmaceutical companies that have substantially greater financial
resources. We expect that our
licensees will continue to develop and fund those products and pay us up-front license fees,
milestone payments, and royalties on product sales if those products are successfully developed and
approved for marketing by the FDA and foreign regulatory agencies. We caution that we may not find
licensees or partners for our programs and many of our development efforts could experience delays,
setbacks and failures, with no assurance that any of our clinical research or our potential
licensees or partners will ever reach the stage of submitting an NDA to the FDA or that any NDA
will be approved. The following table sets forth the status of, and costs attributable to, our proprietary research
and clinical development programs. 21




---



##### Table of Contents



Research and Development Projects and Expenses EstimatedInception
    
    
    Cost toThree Months Ended
    
    
    Six Months Ended
    
    
    Through
    
    
    License orMarch 31,
    
    
    March 31,
    
    
    March 31,
    
    
    CompleteCompany-funded Projects:
    
    2005 (1)
    
    
    2004 (1)
    
    
    2005 (1)
    
    
    2004 (1)
    
    
    2005 (1) (2)
    
    
    Project (1)Develop Neurodex for FDA
marketing approval in
treating PBA. Estimated
cost and timing to reach
NDA decision by end of
2005 (3)
    
    $
    7,408,161
    
    
    $
    2,429,863
    
    
    $
    9,596,683
    
    
    $
    4,200,577
    
    
    $
    27,718,643
    
    
    $
    4.6M
    (4)Develop Neurodex for
neuropathic pain. Phase II
open-label study
completed. Estimated cost
and timing to complete one
Phase III trial and
license the product: up to
2 years (5)
    
    
    1,812,159
    
    
    
    510,594
    
    
    
    1,982,667
    
    
    
    1,106,258
    
    
    
    8,423,273
    
    
    $
    10M
    (6)Development program for
allergy and asthma.
Estimated timing to
complete Phase IIa and
license the product: up to
2 years
    
    
    521,397
    
    
    
    883,086
    
    
    
    1,173,100
    
    
    
    1,950,922
    
    
    
    19,330,159
    
    
    $
    12 MPreclinical
atherosclerosis research
program. Estimated timing
to complete proof of
concept and to license the
product: up to 3 years
    
    
    714,502
    
    
    
    237,196
    
    
    
    1,846,726
    
    
    
    460,673
    
    
    
    5,114,724
    
    
    $
    24 MOther projects involving
monoclonal antibodies and
docosanol
    
    
    507,725
    
    
    
    523,671
    
    
    
    1,022,024
    
    
    
    1,393,311
    
    
    
    14,610,875
    
    
    
    3⁄4
    (7)Partner-funded Project:Preclinical
anti-inflammatory research
program (MIF inhibitor)
    
    
    334,565
    
    
    
    454,115
    
    
    
    583,093
    
    
    
    1,067,212
    
    
    
    10,702,822
    
    
    
    3⁄4
    (8)Government-funded Projects:Preclinical research,
primarily for potential
treatments for genital
herpes and anthrax.
Estimated timing to
complete the various
projects up to 18 months
    
    
    129,661
    
    
    
    337,235
    
    
    
    278,118
    
    
    
    563,176
    
    
    
    2,315,922
    
    
    $
    0.4 M
    (9)Total
    
    $
    11,428,170
    
    
    $
    5,375,760
    
    
    $
    16,482,411
    
    
    $
    10,742,129
    
    
    $
    88,216,418
   (1)
    
    Each project includes allocation of laboratory occupancy costs. M refers to
millions. Estimated costs and timing to complete the projects are subject to the
availability of funds. For each of the projects set forth in the
table, other than Neurodex for PBA and the MIF inhibitor, we are seeking
development partners or licensees to defray part or all of the
ongoing development costs.(2)
    
    Inception dates are on or after October 1, 1998, at which time we began identifying
and tracking programs costs.(3)
    
    The amounts for three-month and six-month periods include $5.8 million which is 80%
of the $1.9 million cash and non-cash charge of $5.3 million related to the acquisition of additional
contractual rights to Neurodex (see Note 11, Related Party Transactions, in Notes to
Condensed Consolidated Financial Statements (Unaudited)).(4)
    
    Total expenditures of $4.6 million include an additional $3.0 million in 2005
calendar year to complete the open label study and the NDA submission fee, estimated to be
$672,000.(5)
    
    The amounts for three-month and six-month periods include $1.4 million which is 20%
of the $1.9 million cash and non-cash charge of $5.3 million related to the acquisition of additional
contractual rights to Neurodex (see Note 11, Related Party Transactions, in Notes to
Condensed Consolidated Financial Statements (Unaudited)).(6)
    
    Licensing and/or co-promotion alternatives are being explored whereby the partner
would fund a portion of clinical development. See Status of R&D Programs and Plans.
Program expenditures for Neurodex for the treatment of neuropathic pain during each of the
listed periods include allocated costs of certain research programs that are shared with
Neurodex for PBA. We are in the process of developing our Phase III clinical study plan
and estimated costs, which include approximately $8.5 million for
a Phase III clinical trial, could change substantially.(7)
    
    The costs and timing to complete these projects are unpredictable because of the
uncertainty of outcomes of the research. 22




---



##### Table of Contents



(8)
    
    Effective April 27, 2005, we entered into a research, development and
commercialization agreement with Novartis, whereby Novartis will be funding all future
development of the project. We estimate our participation to be in the range of $1.5
million to $2.5 million a year, in expenses reimbursable by Novartis, for up to four years.(9)
    
    Represents the remaining balance of state and Federal research grant awards totaling
approximately $438,000 for research related to genital herpes and anthrax. Status of R&D Programs and Plans  Company-funded Projects Neurodex for the treatment of PBA.We began submission of an NDA to the FDA on a rolling basis
on December 16, 2004 and expect to complete our submission in mid-2005. The rolling
process allows Avanir to submit the NDA in modules (reviewable units), which can then be
evaluated by the FDA. Although we have commenced submission of our NDA, the FDA has not, to our
knowledge, yet begun review of the first module. The FDA has indicated that Neurodex would qualify
for a priority review. Once the submission is complete, and assuming that the FDA grants us
priority review, we expect the FDA will take approximately six months to complete its review of the
NDA. Avanir has been engaged in an open-label safety study for the treatment of PBA in a
broad pool of patients who have PBA associated with their underlying neurodegenerative disease or
condition. We expect this open-label study to continue throughout 2005. Neurodex for the treatment of neuropathic pain.We are currently developing our Phase III clinical
development plan for the use of Neurodex in the treatment of neuropathic pain and have included the
costs to conduct one Phase III clinical trial during 2005-2006. Simultaneously, we are evaluating
commercial development alternatives for this indication; including continuing development on our
own or seeking funding from a potential co-promotion partner or potential licensee. There can be
no assurances as to the timing of a license or co-promotion arrangement, if any. Development program for allergy and asthma (IgE regulator).In 2004 we completed a Phase I
clinical trial of our asthma/allergy drug, AVP-13358, in 54 healthy volunteers. The
placebo-controlled study was intended to assess safety, tolerability and pharmacokinetics following
single rising oral doses. Results of the study suggest AVP-13358 was well tolerated at all doses
up through 16 milligrams. The study also demonstrated AVP-13358 was detectable in the bloodstream
at all doses administered and remains in circulation long enough to allow potentially once or twice
daily dosing. We intend to continue to evaluate the safety of the drug by conducting rising
multi-dose studies in healthy patients. Assuming the results of the multi-dose studies are
favorable, we will seek to license the drug to a larger pharmaceutical company for further
development. Development program for atherosclerosis.We are engaged in preclinical research investigating the
use of small, orally active molecules as a potential treatment of atherosclerosis (the build-up of
fatty plaques in blood vessel walls). Our research is focused on developing molecules that can
enhance the naturally occurring process known as reverse cholesterol transport or RCT, whereby
cholesterol is effluxed from the fatty-plaques in blood vessel walls and transported to the liver
for elimination from the body. Preliminary studies in animal models suggest our compounds may
reduce fatty plaques and increase fecal cholesterol excretion. Status of R&D programs and plans  partner-funded project Anti-inflammatory research program (MIF inhibitor).We are currently conducting research on
several potential drug candidates capable of inhibiting or blocking the activity of macrophage
migration inhibitory factor (MIF). Our research indicates that MIF may serve as a potential drug
target in a variety of diseases, including rheumatoid arthritis, Psoriasis, Crohns disease,
colitis and asthma. On April 27, 2005, we entered into a research, development and commercialization agreement with
Novartis to develop orally active small molecule therapeutics targeting MIF as a potential
treatment for inflammatory diseases. Under the terms of the agreement, we are eligible to receive
over $200 million in milestone and royalty payments upon the
achievement of certain specified development, regulatory 23




---



##### Table of Contents



and sales objectives. Under this agreement, we will also receive annual research funding of between $1.5 million
and $2.5 million for up to four years of the agreement. Novartis will assume all responsibility for
product development expenses and both parties will contribute expertise and intellectual property. Status of R&D programs and plans  government-funded projects Government research grants have helped fund research on docosanol-based formulations for the
treatment of genital herpes and the development of antibodies to anthrax toxins, among other
research programs.Approximately $438,000 in aggregate funds remains to be spent in 2005 and
2006 calendar year under existing government research grants. Monoclonal antibodies anthrax toxin.Two of Avanirs most potent anthrax antibodies,
AVP-21D9 and AVP-22G12, appear unique both in mechanism of action and in terms of the binding site
on the anthrax toxin. AVP-21D9 is currently in preclinical development for use as a prophylactic
and therapeutic drug to treat anthrax infections and is being funded
by a two-year $750,000 federal (SBIR) research grant. Much of our work targeting
infectious diseases has been funded by government research grants and
we expect that ongoing development costs will be funded by government
grants. Accordingly, our development plans and timing are currently
partially dependent on the status of these grants. Because all of our monoclonal
antibody research is at a very early preclinical stage of development and is unpredictable in terms
of the outcome, we are unable to predict the cost and timing for development of any antibody or
drug. General and administrative expenses.Our general and administrative expenses for the second
quarter of fiscal 2005 increased to $2.0 million, compared to $1.5 million for the same period a
year ago. The increase of $467,000 or 31% is primarily due to:  
    a $281,000 increase related to legal and other professional services mainly associated
with corporate governance, securities compliance and compliance with the Sarbanes-Oxley
Act of 2002;
    a $261,000 increase related to human resources programs for training, education and staff development; and
    a $39,000 increase in investor relations, primarily because of higher costs to prepare
the annual report, and higher costs related to conference calls and presentation fees. We
expect that costs of compliance with the Sarbanes-Oxley Act will continue to
increase. Sales and marketing expenses.Sales and marketing expenses for the second quarter of fiscal 2005
increased to $1.4 million, compared to $722,000 during the same period in fiscal 2004. Higher
expenses in the second quarter of fiscal 2005 were related to the continued expansion of our
medical education and awareness programs for PBA, market research, and pre-launch activities for
Neurodex, assuming the drug is approved by the FDA for marketing. We expect sales and marketing
expenses by the end of fiscal 2005 will be approximately double overall levels experienced in
fiscal 2004, based on our current commercial development plans for
Neurodex for PBA. Other Income (Expense) For the second quarter of fiscal 2005, interest income increased to $125,000, compared to $57,000
for the same period in the prior year. The increase is primarily due
to a 36% increase in average
balance of cash,
cash equivalents and investments in the quarter ended March 31, 2005 as compared to the same period
in the prior year and a slightly higher average interest rate in fiscal 2005. Net Loss 24




---



##### Table of Contents



For
the second quarter of fiscal 2005, the net loss was $14.1 million, compared to $6.7 million for
the same period a year ago. The net loss per share, basic and diluted, was $0.14 for the second
quarter of fiscal 2005, compared to $0.09 for the same period a year ago. We expect to continue to pursue our drug development strategy focused on
the commercial development of Neurodex, followed by other programs in earlier stages of
development that are in larger therapeutic areas and that we expect will have significant
partnering and licensing potential. Effective in April 2005, Novartis
assumed all responsibility for product development expenses for our
MIF technology. To help fund and develop our other products, we intend to seek
licensees and partners to share the costs of development. These potential license arrangements
could materially change our outlook for future revenues and costs. However, the certainty and
timing of such additional potential arrangements is unpredictable. COMPARISON OF SIX MONTHS ENDED MARCH 31, 2005 AND 2004 Revenues Revenues
for the first six months of fiscal 2005 amounted to $1.5 million, compared to $2.4 million
for the first six months of fiscal 2004. Revenues for the first six months of fiscal 2005
included $928,000 in revenue that we recognized from the sale of certain rights to future Abreva®
royalties to Drug Royalty USA, $300,000 relating to achievement of milestones under license
agreements, $17,000 in sales of the raw material docosanol, and $286,000 from government research
grants. Revenues for the first six months of fiscal year 2004 included $881,000 in revenue that we
recognized from the sale of certain rights to future Abreva royalties to Drug Royalty USA, $770,000
in sales of the raw material docosanol, and $440,000 from government research grants. Expenses Operating Expenses. Total operating expenses for the first six months of fiscal 2005 increased
to $22.8 million, compared to $15.4 million in the same period in fiscal 2004. The
increase in operating expenses was primarily caused by a
$5.7 million, or 53%, increase in
research and development expenses, a $914,000, or 31%, increase in general and administrative
expenses and a $917,000, or 58%, increase in sales and marketing expenses. Research and
development programs accounted for 72% and 70% of total operating expenses for the first six months
of fiscal 2005 and 2004, respectively. General and administrative expenses accounted for 17% and
19% of total operating expenses for the first six months of fiscal 2005 and 2004, respectively.
Sales and marketing expenses accounted for 11% and 10% of total operating expenses for the first
six months of fiscal 2005 and 2004, respectively. These and other costs are more fully described
below. Research and Development Expenses. R&D expenses for the first six months of fiscal 2005 were $16.5
million, compared to $10.7 million in the same period a year
ago. The increase is due primarily to $7.2 million in expenses
related to the acquisition of additional contractual rights to Neurodex (see Note 11, Related Party
Transactions, in Notes to Condensed Consolidated Financial Statements (Unaudited)); offset in part
by a $400,000 decrease in clinical spending on Neurodex in the treatment of pseudobulbar affect (PBA)
in patients with multiple sclerosis. The balance of R&D spending was for other programs, including
pre-clinical research related to inflammation and cholesterol-lowering compounds and antibody
research programs. General and Administrative Expenses. General and administrative expenses for the first six months
of fiscal 2005 amounted to $3.8 million, representing a 31% increase over expenses of $2.9 million
in the same period in the prior year. Higher expenses were attributable to a $275,000 increase
related to human resource programs, a $436,000 increase related to legal and other professional
services associated with corporate governance, compliance with
securities laws and the Sarbanes-Oxley Act of
2002, and a $124,000 increase in outside services for investor
relations activities. 25




---



##### Table of Contents



Sales and Marketing Expenses. Sales and marketing expenses for the first half of fiscal 2005
increased by $917,000 or 58% to $2.5 million, compared to $1.6 million in the same period a year
ago. Higher expenses in the first six months of fiscal 2005 were primarily related to the addition
of medical education and awareness programs for PBA and pre-launch planning activities for
Neurodex. As discussed above, we expect these expenses to continue to increase significantly over the next 12 months as
we prepare for the commercial launch of Neurodex for PBA. Net Loss For
the first six months of fiscal 2005, net loss was $21.1 million, compared to $13.0 million for
the same period a year ago. The basic and diluted net loss per share was $0.22 and $0.18 for the
first six months of fiscal 2005 and 2004, respectively. LIQUIDITY AND CAPITAL RESOURCES As of March 31, 2005, we had cash, cash equivalents and investments in securities totaling $17.0
million, including cash and cash equivalents of $8.2 million, short- and long-term investments of
$7.9 million and restricted investments in securities of approximately $857,000. Our net working
capital balance as of March 31, 2005 was $7.1 million. As of September 30, 2004, we had cash, cash
equivalents and investments in securities totaling $25.9 million, including cash and cash
equivalents of $13.5 million, short- and long-term investments of $11.6 million, and restricted
investments of approximately $857,000. Our net working capital balance as of September 30, 2004
was $16.7 million. Explanations of net cash provided by or used for operating, investing and
financing activities are provided below. IncreaseMarch 31,
    
    
    (Decrease)
    
    
    September 30,2005
    
    
    During Period
    
    
    2004Cash, cash equivalents and investment in securities
    
    $
    16,966,012
    
    
    $
    (8,940,517
    )
    
    $
    25,906,529Cash and cash equivalents
    
    $
    8,206,486
    
    
    $
    (5,287,597
    )
    
    $
    13,494,083Net working capital
    
    $
    7,082,454
    
    
    $
    (9,571,167
    )
    
    $
    16,653,621Six Months Ended
    
    
    Change
    
    
    Six Months EndedMarch 31,
    
    
    Between
    
    
    March 31,2005
    
    
    Periods
    
    
    2004Net cash used for operating activities
    
    $
    (15,172,497
    )
    
    $
    (4,043,798
    )
    
    $
    (11,128,699
    )Net cash provided by (used for) investing activities
    
    
    2,783,034
    
    
    
    3,708,784
    
    
    
    (925,750
    )Net cash provided by financing activities
    
    
    7,101,866
    
    
    
    (664,668
    )
    
    
    7,766,534Net decrease in cash and cash equivalents
    
    $
    (5,287,597
    )
    
    $
    (999,682
    )
    
    $
    (4,287,915
    )
 Operating activities.Net cash used for operating activities amounted to $15.2 million in the
first six months of fiscal 2005, $4.0 million higher than the
same period a year ago. Net cash used in the first half of fiscal
2005 primarily resulted from a net loss of $21.1 million,
reflecting the high levels of spending on our R&D programs combined
with low revenues from existing sources, a $1.0 million decrease
in deferred revenue and a $611,000
increase in prepaid expenses and other assets; offset in part by
non-cash charges of $913,000 in depreciation and amortization and $5.3 million from issuance of common stock relating to payment for Neurodex (see Note 11,
Related Party Transactions, in Notes to Condensed
Consolidated Financial Statements (Unaudited)). The first six months
of fiscal 2005 also included a non-cash charge of $178,000
related to intangible assets abandoned (net of approximately $18,000 in accumulated amortization). During the first half of fiscal 2005,
we abandoned certain therapeutic use patents pending in selected
countries related to potential treatments of allergy and asthma, and
cancer, because we were able to obtain superior claims in
composition-of-matter patents. (See Note 3, Balance Sheet Details
- Intangible Assets in Notes to Condensed Consolidated Financial Statements (Unaudited).) The net cash used for operating activities in the first six months of fiscal 2004 amounted to $11.1
million. During the first six months of fiscal 2004, accounts receivable increased by
approximately $93,000, representing services provided under government grants for which payments
were received after the quarter ended. Also, inventory declined by approximately $198,000 in the
first six months of fiscal 2004, representing the cost of the active ingredient docosanol sold to
various licensees. We intend to replenish our docosanol inventory in the third quarter of fiscal
2005. 26




---



##### Table of Contents



Prepaid
expenses increased to $2.1 million at March 31, 2005 from
$1.5 million at September 30, 2004. The increase is due to
prepayments for additional contracts for services on our clinical
trials and marketing programs for the planned commercial launch of
Neurodex for PBA. Investing activities.Net cash provided by investing activities during the first six months of
fiscal 2005 amounted to $2.8 million, including sales and maturities of investments totaling $7.9
million, partially offset by investments in securities totaling $4.3 million, purchases of property
and equipment of $240,000 and patent costs of $552,000. Net cash used for investing activities
during the first six months of fiscal 2004 amounted to $926,000, including investments in
securities totaling $997,000, purchases of property and equipment of $72,000, and patent costs of
$557,000, partially offset by sales and maturities of investments totaling $700,000. We expect
that capital expenditures for property and equipment will likely increase in the coming quarters as
we make accommodations in our existing facilities for additional sales and marketing personnel that
will be necessary to support commercialization of Neurodex, assuming the drug is approved by the
FDA. (See Managements Discussion and Analysis of Financial Condition and Results of Operations,
Sales and Marketing Expenses.) Financing activities.Net cash provided by financing activities amounted to $7.1 million during
the first six months of fiscal 2005, consisting primarily of $7.0 million received from the sale of
Class A common stock in December 2004. (See Note 10, Shareholders Equity in the Notes to
Condensed Consolidated Financial Statements (Unaudited)). Net cash provided by financing
activities amounted to $7.8 million in the first six months of fiscal 2004, consisting primarily of
$7.5 million received from the sale of Class A common stock and warrants in December 2003. In April 2004, we filed a shelf registration statement on Form S-3 with the SEC to sell an
aggregate of up to $50 million in Class A common stock. In April 2005, we amended this
registration statement to increase the dollar amount of securities registered under the
registration statement to $52.9 million. Our sale of Class A common stock in June 2004,
representing $28.8 million in gross proceeds ($26.5 million net of underwriting discount and costs
of the financing transaction) was the first transaction for the sale of Class A common stock under
the existing shelf registration. In December 2004, we sold an additional $7.0 million in Class A
common stock to an institutional investor at $3.00 per share. In April 2005, we sold to certain
investors $17.1 million in Class A common stock ($15.8 million net of offering expenses and
commissions). No more shares of Class A common stock remained available for sale under the shelf registration
as of May 12, 2005. In September 2004, Avanir entered into an equipment line of credit with GE Healthcare
Financial Services for financing of up to $1.4 million. As of March 31, 2005, the outstanding
balance of the line of credit was approximately $821,000. On March 8, 2005, we entered into an Asset Purchase Agreement, pursuant to which our wholly owned
subsidiary, Avanir Holding Company, acquired from IriSys certain additional contractual rights to
Neurodex. As a result, through our wholly owned subsidiary we hold the exclusive worldwide
marketing rights to Neurodex for certain indications as set forth
under the License Agreement and have no further license arrangements
with IriSys.
We will be obligated to
pay CNS milestone payments
upon achievement of certain future events relating to the FDAs
regulatory approval process for Neurodex and
a royalty on commercial sales of Neurodex, if and when the drug is approved by the FDA for
commercialization. Under certain circumstances, we may have the obligation to pay CNS a share of
net revenues received if we sublicense Neurodex to a third party. As of the date of this report,
we have not triggered any of these milestone or royalty payments and, therefore, no payment is due CNS.
Based on anticipated performance in 2005, we believe it is reasonably likely that we will pay a
$75,000 milestone in July 2005 upon the accepted filing of our NDA for Neurodex. We also expect to
pay an additional $75,000 milestone if the FDA approves our NDA. 27




---



##### Table of Contents



In connection with the Asset Purchase Agreement, we paid IriSys a purchase price of $7,225,000
including $1,925,000 in cash and 2,000,000 shares of our Class A common stock with a fair value of
$5,300,000. The fair value of the common stock was calculated at $2.65 per share using the 5-day
average closing price of our common stock, beginning two days before and ending two days after the
close and announcement of the agreement on March 9, 2005. MANAGEMENT OUTLOOK We believe that cash, cash
equivalents, and investments in securities of approximately
$31.4 million at May 12, 2005, plus
anticipated future revenues, should be sufficient to sustain our planned level of operations for at
least the next 12 months. However, to pay the $672,000 NDA filing fee and continue to fund the
development of our new drug candidates and technology platforms and
the expected product launch of
Neurodex during the next two years (assuming that Neurodex is approved for marketing by the FDA),
we will need to raise a significant amount of additional capital and expect to continue to pursue various alternatives for
raising capital during this period. Potential alternatives that we are considering for
raising capital include, but are not limited to, partnering arrangements where partners share
development costs, issuance of debt or equity securities, and licensing or sales of one or more of
our platform technologies or new drug candidates. For information
regarding the risks associated with our need to raise capital to
fund our ongoing and planned operations, please see Risk
Factors That Might Affect Future Operations. CRITICAL ACCOUNTING POLICIES AND ESTIMATES The preparation of financial statements in accordance with accounting principles generally accepted
in the United States requires that management make a number of assumptions and estimates that
affect the reported amounts of assets, liabilities, revenues and expenses in our consolidated
financial statements and accompanying notes. Management bases its estimates on historical
information and assumptions believed to be reasonable. Although these estimates are based on
managements best knowledge of current events and circumstances that may impact us in the future,
actual results may differ from these estimates. Our critical accounting policies are those that affect our financial statements materially and
involve a significant level of judgment by management. Our critical accounting policies regarding
revenue recognition are in the following areas: milestone payments in license agreements, royalties
on licensed products, sale of rights to future royalties, and recognition of revenues in research
contracts. Our critical accounting policies also include recognition of expenses in research
contracts and research and development expenses and the valuation of long-lived and intangible assets. Milestone Payments in License Agreements We recognize revenues from license fees when the performance requirements have been met, the fee is
fixed or determinable, and collection of fees is probable. We defer revenues and recognize them
ratably over the life of the agreement when we have continuing obligations to perform under the
agreement. We
have license agreements for our docosanal 10% cream and MIF
technology and expect to enter into additional license
agreements in the future. We expect that each license agreement will have its own set of
circumstances and terms of 28




---



##### Table of Contents



performance. We will consider the specific facts and circumstances of
each license agreement to determine the appropriate revenue recognition for such items, including
nonrefundable up-front fees and milestone payments and taking into consideration when the earnings
process is complete and collection is reasonably assured. Royalties on Licensed Products We recognize royalty revenues from our licensed products based on the reported sales by our
licensees and computed in accordance with the specific terms of the license agreements. Since the
launch of Abreva in October 2000 through March 31, 2005, substantially all of our royalties have
come from GlaxoSmithKline. We have entered into additional license agreements that contain
royalties as a source of revenues, and we expect to enter into additional similar license
agreements with foreign-based companies. Sale of Rights to Future Abreva® Royalties In fiscal 2003, we sold an undivided interest in our license agreement with SB to Drug Royalty USA
for $24.1 million. Because of our ongoing involvement with SB in earning future royalty revenues,
we have recorded the amounts received from Drug Royalty USA, net of costs of the transaction and
forgiveness of certain advances, as deferred revenue. The amount recorded as deferred revenue is
being recognized as revenue under the units-of-revenue method over the period from October 2002
through April 2014. Under this method, the amount of deferred revenue being recognized as revenue
in each period is calculated by multiplying (i) the ratio of the royalty payments due to Drug
Royalty USA for the period to the total remaining royalties that we expect SB will pay Drug Royalty
USA over the term of the agreement, by (ii) the unamortized deferred revenue amount. The portion
of deferred revenue classified as a current liability represents the amount we expect to realize as
revenue within the next 12 months. (See Note 5, Deferred Revenue, in the Notes to Condensed
Consolidated Financial Statements (Unaudited).) Recognition of Revenues in Research Contracts We may enter into research contracts or collaborations that have obligations to deliver to the
customer multiple products and/or services (multiple deliverables) in exchange for fees or
milestone payments. Such contracts could include antibody generation services agreements and other
forms of research collaborations, as discussed below. Antibody generation services.As of March 31, 2005, we were engaged in work on one research
collaboration agreement that had research initiation fees. In this type of agreement, the customer
provides us with the target antigens. We then perform research services to develop potential
antibodies for those antigens. If we are able to estimate the period of service in the contract in
advance of beginning the work, we recognize such research initiation fees ratably as revenue
over the estimated period of service. If
we are unable to identify the period of service in the contract in advance of beginning the work,
we defer research initiation fees and recognize such fees as revenue once we have completed our
efforts to create the antibodies. In the research phases of the collaboration agreement,
we may receive payment either to start a research phase or to complete a research phase (including
receipt by the customer of the deliverable). We recognize revenue once the product has been
delivered because the earning process would be complete and an exchange has been made. Factors
taken into consideration in recognizing revenues include the following:  
    The performance criteria have been met;
    Any deliverable products or services are not essential to the functionality of the
delivered products or services; and 29




---



##### Table of Contents




    Payment for the delivered products or services is not contingent on delivery of the
remaining products or services. Other research contracts.As with all our research contracts, including the up-front initiation
fee, we defer revenue recognition until services have been rendered or products (e.g. developed
antibodies) are delivered. The milestones established within the contract are typically set to
approximate the effort associated with the completion of each phase. Recognition of Expenses
in Outsourced Research Contracts Pursuant to managements assessment of the progress that has been made on clinical trials and
services provided in other research contracts, we recognize expenses as the services are provided.
Several of our contracts extend across multiple reporting periods, including our largest contract,
representing an $8.5 million Phase III clinical trial contract as of March 31, 2005. A 3% variance
in our estimate of the work completed in our largest contract could increase or decrease our
operating expenses by $255,000. Such contracts require an assessment of the work that has been
completed during the period, including measurement of progress, analysis of data that justifies the
progress, and finally, managements judgment. We assess our obligations to make milestone payments that may become due under licensed or acquired
technology to determine whether the payments should be expensed or capitalized. We charge
milestone payments to research and development expense when:  
    The technology is in the early stage of development and has no alternative uses;
    There is substantial uncertainty of the technology or product being successful;
    There will be difficulty in completing the remaining development; and
    There is substantial cost to complete the work. Research and development expenses Research and development expenses consist of expenses incurred in performing research and development activities including salaries
and benefits, facilities and other overhead expenses, clinical trails, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred.
Up-front payments paid to collaborators, in exchange for the avoidance of potential future milestone and royalty payments on licensed technology are also charged to research and development expense when
the drug is still in the development stage, has not been approved by the FDA for commercialization and concurrently has no alternative uses. Acquired contractual
rights. Payments to acquire contractual rights to a licensed
technology or drug candidate are expensed as incurred
when there is uncertainty in receiving future economic benefits from
the acquired contractual rights. We consider the future economic benefits
from the acquired contractual rights to a drug candidate to be
uncertain until such drug candidate is approved by the FDA or when
other significant risk factors are abated. Capitalization and Valuation of Long-Lived and Intangible Assets Intangible
assets with finite useful lives consist of capitalized legal costs incurred in connection with patents, patent applications pending,
trademark applications and license agreements. We amortize costs of approved patents, patent
applications pending and license agreements over their estimated useful lives, or terms of the
agreements, whichever are shorter. For patents pending, we amortize the costs over the shorter of
a period of twenty years from the date of filing the application or, if licensed, the term of the
license agreement. We re-assess the useful lives of patents when they are issued, or whenever
events or changes in circumstances indicate the useful lives may have changes. For patent and
trademark applications that we abandon, we charge the remaining unamortized accumulated costs to
expense. Our amortizable intangible assets consist of the costs of patents, patent applications
pending and licenses. Intangible assets are evaluated for impairment whenever events or changes in circumstances indicate
that their carrying value may not be recoverable. If the review indicates that long-lived assets
are not recoverable (i.e. the carrying amount is less than the future projected undiscounted cash flows),
their carrying amount would be reduced to fair value. Factors we consider important that could
trigger an impairment review include the following:  
    A significant underperformance relative to expected historical or projected future
operating results;
    A significant change in the manner of our use of the acquired asset or the strategy for
our overall business; and/or
    A significant negative industry or economic trend. 30




---



##### Table of Contents



When we determine that the carrying value of intangible assets or long-lived assets are not
recoverable based upon the existence of one or more of the above indicators of impairment, we may
be required to record impairment charges for these assets that have not been previously recorded. As of March 31, 2005, our largest group of intangible assets with finite lives was patents and
patents pending for our IgE down-regulation technology, having net intangible assets of
approximately $1.0 million Any setback or failure in our IgE technology, currently in Phase I
clinical development for the treatment of allergy and asthma, could cause a re-assessment of the
value of this technology and possible write-down of all or a portion of the
costs of these assets. RECENT ACCOUNTING PRONOUNCEMENTS See Note 2, Stock-based Compensation and Note 12, Recent Accounting Pronouncements in the Notes
to Condensed Consolidated Financial Statements (Unaudited) for a discussion of recent accounting
pronouncements and their effect, if any, on our financial condition or results of operations. RISK FACTORS THAT MIGHT AFFECT FUTURE OPERATIONS Risks Relating to Our Business We have a history of losses and we may never achieve or maintain profitability. To date, we have experienced significant operating losses in funding the research, development and
clinical testing of our drug candidates and we expect to continue to incur substantial operating
losses through at least fiscal 2006. As of March 31, 2005, our accumulated deficit was
approximately $145.5 million. To achieve profitability, we would need to generate significant
additional revenue with positive gross margins to offset our other operating expenses.
Additionally, we intend to increase our pre-launch activities and sales and marketing efforts over
the next several quarters as we continue our rolling submission of an NDA to the FDA for Neurodex
and, thereafter, await the FDAs decision. We could also increase spending on our preclinical
programs to the extent our progress in development is favorable. Although we are seeking to
negotiate revenue-generating licenses and/or co-promotion arrangements for docosanol 10% cream and

other product candidates, we may not find attractive arrangements, if at all, and any such
arrangements may not provide adequate revenues to cover future operating expenses. Increases in
expenditures may not be offset by new or adequate sources of revenues, and as a result, we may not
achieve or maintain profitability. We are currently in the process of submitting our Neurodex clinical trial results to the FDA for
review and approval prior to U.S. commercialization. Any delay or adverse decisions in the
regulatory review or approval process may harm our prospects and could harm our stock price. We began submission of a NDA for Neurodex to the FDA in December 2004 under a rolling submission
basis, and we must obtain FDA approval prior to commercialization in the United States. A rolling
submission allows us to submit the NDA in reviewable modules. To date, we have submitted 2 of
3 modules and we currently expect to complete our submission in mid-2005. We may not be able to
maintain our planned schedule and may not complete our submission in a timely manner. Any delays
in our submission or in the FDAs review or approval could delay market launch and increase the
volatility of our stock price and may result in additional operating losses, which would likely
increase our cash requirements. Based on communications with the FDA, we expect that the final submission will activate a priority
review by the FDA, which is a six-month review period for the NDA. However, the process of
obtaining FDA approval often takes more than one year and can vary substantially based upon the
type, complexity and novelty of the products involved. If we complete the submission of an NDA for
Neurodex, the FDA must decide whether to accept or reject the submission for filing. The FDAs
official filing of an NDA is the action that begins the applications substantive review. The FDA
may refuse to file an NDA 31




---



##### Table of Contents



for review for many reasons, including if the submission contains
insufficient data to demonstrate efficacy and/or safety. We cannot be certain that our NDA
submission would be accepted for filing and reviewed by the FDA or that we would be able to respond
to any requests during the review period in a timely manner without delaying potential action on
our request for approval. We also cannot be certain that Neurodex will receive a favorable recommendation from any FDA
advisory committees or be approved for marketing by the FDA. Even if the FDA grants marketing
approval for Neurodex, we cannot be certain that we will be able to obtain the labeling claims
necessary or desirable for the promotion of the product. In addition, delays in approvals or
rejections of marketing applications may be based upon many factors, including regulatory requests
for additional analyses, reports, data and/or studies, regulatory questions regarding data and
results, changes in regulatory policy during the period of product development and/or the emergence
of new information regarding our products or other products. Recent public announcements regarding
safety problems with certain approved drugs may affect the FDAs policies regarding safety data for
new drug applications and may result in the FDA requiring additional safety data before accepting
our planned NDA submission, as well as closer surveillance after commercialization if the drug is
approved. We have yet to market or sell Neurodex or any of our other potential products. Although we may market Neurodex in the United States through
a contract sales organization, assuming Neurodex is
approved by the FDA, we have never before marketed or sold any pharmaceutical products. In order
to market or co-market Neurodex or certain other drug candidates, we will need to hire a
significant number of people with relevant pharmaceutical experience to staff our sales management
team and marketing group, and possibly also to make appropriate arrangements with collaborative
partners. If we cannot develop the required marketing and sales expertise internally or through
our partnering arrangements, our ability to generate revenue from product sales will likely suffer. In international markets, we intend to rely on collaborative partners to obtain regulatory
approvals, and to market and sell our products in those markets. We have not yet entered into any
collaborative arrangement with respect to marketing or selling Neurodex, with the exception of one
such agreement relating to Israel. We cannot guarantee that we will be able to enter into any
other arrangements on terms favorable to us, or at all. If we are able to enter into marketing and
selling arrangements with collaborative partners, we cannot assure you that such marketing
collaborators will apply adequate resources and skills to their responsibilities, or that their
marketing efforts will be successful. If we are unable to enter into favorable collaborative
arrangements with respect to marketing or selling Neurodex or docosanol 10% cream or our marketing
collaborators efforts are not successful, our ability to generate revenue from product sales will
suffer. We expect that we will need to raise additional capital to fund ongoing operations through at least
2006. If we are unable to raise additional capital, we may be forced to curtail operations. If we
succeed
in raising additional capital through a licensing or financing transaction, it may affect our stock
price and future revenues. In order to maintain sufficient cash and investments to fund future operations and to prepare for
the commercialization of Neurodex, we will need to raise significant additional capital. We
expect to seek to raise additional capital over the next 12 to 24 months through various
alternatives, including licensing or sales of our technologies and drug candidates and selling
shares of our Class A common stock.  
    If we raise capital through licensing or sales of one or more of our technologies or
drug candidates, then we may not realize revenues from sales of any of our products that
are successfully developed, approved by the FDA and marketed, or our share of such revenues
may be substantially reduced. If we license any of our technologies or drug candidates,
then the development of these products or technologies will no longer be in our control. A
licensee might 32




---



##### Table of Contents



never reach any of the payment milestones in a license agreement. Further,
if we sell any of our technologies or drug candidates, the sales price may not fully cover
our investment in such technology or drug candidate.  
    If we raise capital by issuing additional shares of Class A common stock at a price per
share less than the then-current market price per share, the value of the shares of Class A
common stock then outstanding may be reduced. Further, even if we were to sell shares of
common stock at prices equal to or higher than the current market price, the issuance of
additional shares may depress the market price of our Class A common stock and will dilute
voting rights of our other shareholders. We may not be able to raise capital on terms that we find acceptable, or at all. If we are unable
to raise additional capital to fund future operations, then we may not be able to execute our
commercialization plans for Neurodex and may be required to reduce operations or defer or abandon
one or more of our clinical or pre-clinical research programs. Any of these actions could decrease
our stock price. Developing and testing a drug candidate is a very expensive and time-consuming process that may not
ultimately lead to a marketable product. The drug development process is lengthy and capital-intensive. Since September 1998, we have spent
approximately $88.2 million in preclinical and clinical studies researching the safety and efficacy
of our drug candidates and potential drug candidates. If any of our drug candidates fail to
demonstrate the desired safety and efficacy, we may abandon the development of the compound, in
which event we would not recover our expenditures incurred to date for that compound. If a
compound appears to be safe and effective in preclinical studies, we may decide to proceed with
human clinical trials. The full complement of clinical trials required to obtain regulatory
approval for many of our drug development programs exceeds our available capital. Because of our
limited financial resources, we may be required to license the compound to a pharmaceutical company
with greater financial resources in order to complete the development of the drug. We may be
unable to find a large pharmaceutical company interested in licensing the drug or, if we do locate
such a licensee, the proposed license terms may not be acceptable to us. In the event that we are
unable to find a large pharmaceutical partner or licensee on acceptable terms, we may be forced to
abandon one or more of our drug candidates. We expect our quarterly operating results to fluctuate significantly from period-to-period for a
number of reasons. Historically, we have had only limited recurring revenue. As a result, operating results have
been, and will continue to be, subject to significant quarterly fluctuations based on a variety of
factors, including:  
    Co-promotion or license arrangements We are currently seeking co-promotion or
licensing partners for docosanol 10% cream and Neurodex, as well as for our compounds
targeting IgE (allergy and asthma) and apolipoprotein A1
(atherosclerosis). It is difficult to predict whether any of these discussions will result
in a partnering or license arrangement and what the financial terms of such an arrangement
might be. If we do enter into any such arrangements, the recognition of the revenue under
those arrangements may depend on the efforts and performance of our licensees or partners
in reaching milestones that are outside our control. Such milestones may include specific
events, such as regulatory approval, product launch, the passage of time, or reaching a
sales threshold.
    Limited rights to future Abreva royalties In December 2002, we sold to Drug Royalty
USA the rights to a substantial portion of our future royalty revenues from sales of Abreva
by GlaxoSmithKline. We will not receive any future royalty payments unless and until
annual Abreva wholesale sales exceed $62 million, at which time we will receive one-half of
the stated 33




---



##### Table of Contents



royalty rate on any excess sales. We estimate that wholesale sales reached
approximately 89% of the $62 million threshold in 2004. We expect that any royalty
payments on these excess sales, if any, would occur only once a year, after the end of each
calendar year.
    Concentration of significant customers, suppliers and industries Milestone payments,
royalties earned, and revenues recognized from the sale of rights to royalties from a
single licensee (GlaxoSmithKline) accounted for approximately 48%, 73% and 95% of our
fiscal 2004, 2003 and 2002 revenues, respectively. We have now received all of the
milestone payments from GlaxoSmithKline for North America. With the sale of our Abreva
royalty rights to Drug Royalty USA, future royalty payments from GlaxoSmithKline will come
exclusively from our remaining 50% share of Abreva royalties on contract sales in excess of
$62 million a year. Additionally, we purchase the raw material docosanol from a sole
foreign supplier that has been approved by the FDA for manufacturing. Any disturbances or
delays in the manufacture of docosanol or other raw materials for our products and clinical
research programs could seriously and adversely affect our business.
    Acquisitions/alliances If, in the future, we acquire technologies, products, or
businesses, or we form alliances with companies requiring technology investments or
commitments, we will face a number of risks to our business. The risks that we may
encounter include those associated with integrating operations, personnel, and technologies
acquired or licensed, and the potential for unknown liabilities of the acquired business.
Our business and operating results on a quarterly basis could be adversely affected if any
or our acquisition or alliance activities, to the extent they exist in the future, are not
successful. Our stock price is highly volatile and investors may not be able to sell their shares at or above
the price they pay for them. The market price of our Class A common stock has been, and is likely to continue to be, highly
volatile. The following factors, among others, could have a significant impact on the market price
of our Class A common stock:  
    Unfavorable announcements by us regarding our NDA submission for Neurodex, clinical
trial results or results of operations;
    Our success or failure in entering into license and/or co-promotion arrangements for our
products and product candidates;
    Delays in meeting goals or performance milestones by us or our marketing partners;
    Comments made by securities analysts, including changes in their recommendations;
    Announcements of financing transactions and/or future sales of equity or debt securities;
    Announcements by us of significant acquisitions, strategic partnerships, joint ventures
or capital commitments;
    Sales of our Class A common stock by our directors, officers or significant shareholders;
    Announcements by our competitors of clinical trial results or product approvals; and
    Market and economic conditions. In addition, the market for biotechnology and pharmaceutical stocks has experienced significant
price and volume fluctuations that are frequently unrelated to operating performance. This price
volatility is often more pronounced for companies with a low stock price and a small market
capitalization, such as ours. These broad market and industry factors might seriously harm the
market price of our Class A common stock, regardless of our operating performance. A significant decline in our stock price could also result in our Class A common stock being
delisted from the American Stock Exchange and could lead to the filing of lawsuits, including
securities class action lawsuits. Any such lawsuits against us would result in substantial costs,
potential liabilities and the diversion of managements attention and resources. 34




---



##### Table of Contents



Changes in board and management composition could adversely affect our operations. Since September 2004, three new directors have joined our board and we have recently appointed a
new chairman. Our Corporate Governance Committee is also currently conducting a search for a
director candidate who may replace one of our incumbent directors. Additionally, we are currently
recruiting senior-level sales and marketing personnel to add to our management and we anticipate
that we could experience other changes in management and infrastructure as we expand our
organization, prepare for the commercialization of Neurodex, and effect our transition from a
research and development company to a pharmaceutical company. These changes may be
disruptive, and we may experience difficulties in retaining new directors, attracting and
integrating new members of the management team, and in transitioning our operating activities. Our inability to attract and retain key management and scientific personnel could negatively affect
our business. The industry in which we compete has a high level of employee mobility and aggressive recruiting of
skilled personnel. This type of environment creates intense competition for qualified personnel,
particularly in product research and development, sales and marketing, and accounting and finance,
and the loss of any of our executive officers or other key employees could adversely affect our
operations. Other than our chief executive officer, we do not have employment agreements with any
of our executive officers and do not have key person life insurance policies for any of our
executives. In
order to expand our company as planned and effect our transition to a
pharmaceutical
company, we will need to hire, train, retain and motivate high quality personnel, including sales
and marketing personnel for the commercialization of Neurodex. Any inability to hire qualified
sales and marketing personnel would harm our commercialization plans. Additionally, if we were to
lose one or more of our key scientists, then we would likely lose some portion of our institutional
knowledge and technical know-how, potentially causing a substantial delay in one or more of our
development programs until adequate replacement personnel could be hired and trained. Our patents may be challenged and our pending patents may be denied. Either result would seriously
jeopardize our ability to compete in the intended markets for our proposed products. We rely substantially on the protection of our intellectual property through our ownership or
control of 95 issued patents and 325 patent applications. Patents and patent applications owned or
licensed by us include docosanol-related products and technologies, Neurodex, compounds capable of
regulating the target IgE in controlling symptoms of allergy and asthma, compounds capable of
regulating the target MIF in treatment of inflammatory diseases, compounds targeting apolipoprotein
A1 for the treatment of atherosclerosis, and Xenerex technologies for developing monoclonal
antibodies. Because of the competitive nature of the biopharmaceutical industry, we cannot assure
you that:  
    The claims in any pending patent applications will be allowed or that patents will be
granted; 36




---



##### Table of Contents




    Present and future competitors will not develop similar or superior technologies
independently, duplicate our technologies or design around the patented aspects of our
technologies;
    Our proposed technologies will not infringe other patents or rights owned by others,
including licenses that may be not be available to us;
    Any of our issued patents will provide us with significant competitive advantages; or
    Challenges will not be instituted against the validity or enforceability of any patent
that we own or, if instituted, that these challenges will not be successful. We depend on third parties to manufacture compounds for our drugs and drug candidates. The failure
of these third parties to perform successfully could harm our business. We have utilized, and intend to continue utilizing, third parties to manufacture docosanol 10%
cream, Neurodex, active pharmaceutical ingredients, and supplies for our other drug candidates. We
have no experience in manufacturing and do not have any manufacturing facilities. Currently, we
have only a single supplier for the raw material docosanol and the finished product for Neurodex
and we do not have any long-term agreements in place with either of these suppliers. Any delays or
difficulties in obtaining Neurodex could delay our clinical trials for neuropathic pain and delay
the commercialization of Neurodex for pseudobulbar affect. Additionally, although we and
GlaxoSmithKline maintain a strategic reserve of docosanol to mitigate against a short-term supply
disruption, any sustained disruption of our docosanol supply could harm our operations. Because we depend on clinical research centers and other contractors for clinical testing and for
certain research and development activities, the results of our clinical trials and such research
activities are, to a certain extent, beyond our control. The nature of clinical trials and our business strategy of outsourcing a substantial portion of our
research require that we rely on clinical research centers and other contractors to assist us with
research and development and clinical testing activities. As a result, our success depends
partially on the success of these third parties in performing their responsibilities. Although we
pre-qualify our contractors and we believe that they will fully perform their contractual
obligations, we cannot directly control the adequacy and timeliness of the resources and expertise
that they apply to these activities. If our contractors do not perform their activities in an
adequate or timely manner, the development and commercialization of our drug candidates could be
delayed. Developing new pharmaceutical products for human use involves product liability risks, for which we
currently have limited insurance coverage. The testing, marketing, and sale of pharmaceutical products involves the risk of product liability
claims by consumers and other third parties. We maintain product liability insurance coverage for
our clinical trials in the amount of $5 million per incident and $5 million in the aggregate.
However, product liability claims can be high in the pharmaceutical industry and our insurance may
not sufficiently cover our actual liabilities. Additionally, our
insurance carriers may attempt to deny coverage in certain instances. If a suit against our business or proposed products
is successful, then the lack of or 37




---



##### Table of Contents



insufficiency of insurance coverage could affect materially and
adversely our business and financial condition. Furthermore, various distributors of
pharmaceutical products require minimum product liability insurance coverage before their purchase
or acceptance of products for distribution. Failure to satisfy these insurance requirements could
impede our ability to achieve broad distribution of our proposed products. Abreva® faces competition from a number of existing and well-established products and the companies
that market these products. We have the opportunity to earn royalties on Abreva product wholesale sales if sales exceed $62
million a year. We estimate that wholesale sales reached approximately 89% of the $62 million
threshold in 2005. Abreva competes with several other products for oral-facial herpes currently on
the market in the U.S., as well as other products or potential products that are or may be under
development or undergoing FDA review. Many of these products are well established and are marketed
by large pharmaceutical companies with substantial resources and significant marketing experience.
As a result of this competition, annual wholesales sales of Abreva may never reach a level where we
will participate in further royalty income from this product. Our future financial results will be affected by changes in the accounting rules governing the
recognition of stock-based compensation expense. We measure compensation expense for our employee stock compensation plans under the intrinsic value
method of accounting prescribed by Accounting Principles Board Opinion No. 25, Accounting for
Stock Issued to Employees. In addition, we provide pro forma disclosures of our operating results
in our Notes to Consolidated Financial Statements as if the fair value method of accounting had
been applied in accordance with FAS 123R, Share-based
Payment. Had we
accounted for our compensation expense under the fair value method
accounting prescribed by FAS 123R, the charges would have been significantly higher, by approximately $1,003,000, $1,554,000 and
$2,176,000 during fiscal 2004, 2003, and 2002, respectively. The planned effective date for proposed changes
to accounting rules concerning the recognition of stock option
compensation expense will be the fiscal year beginning
October 1, 2005. We and
other companies will be required to measure compensation expense using the fair value method, which
will adversely affect our results of operations by reducing our income or increasing our losses. Business interruptions could adversely affect our business. Our operations are vulnerable to interruption by fire, earthquake, power loss, telecommunications
failure, and other events beyond our control. For example, during 2001 and again in 2003, we
experienced electrical power outages lasting several hours. The loss of electrical power for any
significant periods of time could adversely affect our ability to conduct experiments and could
also harm our vendors. Further, we could lose valuable data made to date in experiments currently
underway. We have mitigated the severity of power losses by installing emergency power equipment,
which we have used on several occasions to supply electricity to the areas that we consider to be
the most critical to our operations. However, the emergency power units do not cover all of our
electrical needs and, further, they might not operate properly in the event of a power loss. The board of directors has the authority to effect a reverse stock split within a stated range
until March 16, 2006. If implemented, the reverse stock split may negatively affect the price and
liquidity of our Class A common stock. At our 2005 Annual Meeting of Shareholders, the board of directors received the authority to
implement, within its discretion and for a period of one year, a reverse split of our Class A
common stock within a range of 1:2 to 1:5. If the board of directors were to effect a reverse stock
split, the bid price of the Class A common stock may not continue at a level in proportion to the
reduction in the number of outstanding shares resulting from the reverse stock split. For example,
if the board of directors decided to implement a reverse stock split at a ratio of 1-for-5, the
post-split market price of our Class A common stock might not continue at a level at least five
times greater than the pre-split price. Accordingly, the total market capitalization of our Class
A common stock after a reverse stock split, if implemented, could be lower than the total market
capitalization before the reverse stock split. Additionally, the liquidity of our Class A common
stock could be affected adversely by the reduced number of shares outstanding after the reverse
stock split. Avanir and its licensees may not be successful in obtaining regulatory approval of
docosanol 10% cream immediately as an OTC product in additional countries, or in licensing,
marketing and selling the product in any other countries. Currently, docosanol 10% cream is approved for sale in the United States, Canada, Korea, Israel,
Sweden, Spain, Portugal, Denmark, Norway, Finland, Greece and Cyprus. We are currently seeking
approval in various other countries in the European Union and intend to seek approval in Japan.
Avanir and its licensees face a variety of risks in foreign countries in obtaining
regulatory approval and in marketing and selling docosanol 10% cream, including:  
    Regulatory approval requirements differ by country, and obtaining approvals to market
the drug in foreign countries may be difficult to obtain, may require additional costly and
time consuming clinical trials, or may require being a prescription drug first before
obtaining sufficient experience to warrant approval as an OTC product;
    Building product awareness of a new drug, whether prescription or OTC, among customers
or retail store decision makers may require a substantial amount of product promotion,
which does not guarantee success:
    Consumers may not perceive that docosanol 10% cream is superior to existing and
potentially new OTC products for oral herpes;
    Acceptance of docosanol 10% cream in the OTC consumer market may not be widespread; and
    Potential price erosion could occur due to competitive products and responses to our
products introduction. Foreign sales of docosanol 10% cream and other potential products are subject to various foreign
trade risks. Our license agreement with GlaxoSmithKline is for the United States and Canada. We also have
exclusive license agreements for docosanol 10% cream for approximately fourteen other countries.
We are holding discussions with other potential licensees for marketing and selling docosanol 10%
cream in other countries not already licensed. However, we may not finalize any license or
distribution arrangements for other territories on a timely basis or on favorable terms, if at all.
Further, our foreign licensees expose us to various foreign trade risks relating to development
and marketing of docosanol 10% cream. We may arrange for contracts in the future for the
manufacture, marketing and distribution of docosanol 10% cream overseas by foreign licensees, which
will be substantially outside our control. Even if we are able to obtain experienced licensees in
foreign markets, specific risks that could impact significantly our potential revenues on foreign
sale include:  
    Difficulties in obtaining regulatory approval of docosanol 10% cream in foreign countries;
    Changes in the regulatory and competitive environments in foreign countries;
    Changes in a specific countrys or regions political or economic conditions;
    War, terrorism or natural disasters;
    Difficulty in finding foreign partners with sufficient capital to effectively launch,
market and promote the product;
    Manufacturing and shipping delays;
    Difficulties in managing operations across disparate geographic areas;
    Fluctuations in foreign exchange rates;
    Prices of competitive products;
    Difficulties associated with enforcing agreements through foreign legal systems;
    Trade protection measures, including customs duties and export quotas; and
    Foreign tax withholding laws. Risks Relating to Our Industry The pharmaceutical industry is highly competitive and most of our competitors are larger and have
greater resources. As a result, we face significant competitive hurdles. 38




---



##### Table of Contents



The pharmaceutical and biotechnology industries are highly competitive and subject to significant
and rapid technological change. We compete with hundreds of companies that develop and market
products and technologies in similar areas as our research. Additionally, many physicians
prescribe medications for indications other than those for which a certain drug has been approved
(so called off-label use). For example, if the FDA approves Neurodex for marketing as a
treatment of PBA, physicians may continue prescribing other products in an off-label manner for the
treatment of this condition, including:  
    Antidepressants, such as ProzacÒ, CelexaÒ, ZoloftÒ, PaxilÒ,
ElavilÒ and PamelorÒ and others;
    Atypical antipsychotics agents, such as ZyprexaÒ, ResperdalÒ,
AbilifyÒ, GeodonÒ and others; and
    Other agents, such as SymmetrelÒ and Lithium Our competitors may have specific expertise and technologies that are better than ours and many of
these companies, either alone or together with their research partners, have substantially greater
financial resources, larger research and development staffs and substantially greater experience
than we do. Accordingly, our competitors may develop a competing product approved specifically for
the treatment of PBA. If we commence commercial sales for Neurodex, we may potentially be competing
with other companies and their products with respect to manufacturing efficiencies and marketing
capabilities, areas where we have limited or no direct experience. Our industry is highly regulated and our failure or inability to comply with government regulations
regarding the development, production, testing, manufacturing and marketing of our products may
adversely affect our operations. Government authorities in the U.S., including the FDA, and other countries highly regulate the
development, production, testing, manufacturing and marketing of pharmaceutical products. The
clinical testing and regulatory approval process can take many years and requires the expenditure
of substantial resources. Failure to obtain, or delays in obtaining, these approvals will
adversely affect our business operations, including our ability to commence marketing of any of the
proposed products. We may find it
necessary to use a significant portion of our financial resources for research and development and
the clinical trials necessary to obtain these approvals for our proposed products. We will
continue to incur costs of development without any assurance that we will ever obtain regulatory
approvals for any of our products under development. Additionally, we cannot predict the extent to
which adverse government regulations might arise from future U.S. or foreign legislative or
administrative actions. Moreover, we cannot predict with accuracy the effects of any future
changes in the regulatory approval process and in the domestic health care system for which we
develop our products, or the costs of on-going compliance regulations after marketing approval has
been obtained. Future changes could affect adversely the time frame required for regulatory
review, our financial resources, and the sales prices of our proposed products, if approved for
sale. Companies in our industry must protect their intellectual property rights and operate without
infringing on or misappropriating the proprietary rights of others. Our inability to do so could
be costly and could significantly affect our business prospects. Pharmaceutical companies such as Avanirrely heavily on intellectual property rights to
protect their innovations. Although we attempt to protect these rights by regularly filing patent
applications and requiring all employees to sign confidentiality agreements, we cannot assure you
that patents will be issued, that secrecy obligations will be honored, or that others will not
independently develop similar or superior technology. Additionally, if our consultants, key
employees or other third parties apply technological information independently developed by them or
by others to our projects, then disputes may arise as to the ownership rights of these innovations. 39




---



##### Table of Contents



Even if we successfully preserve our intellectual property rights, other biotechnology or
pharmaceutical companies may allege that our technology infringes on their rights. Intellectual
property litigation is costly, and even if we were to prevail in such a dispute, the cost of
litigation would adversely affect our business, financial condition and results of operations.
Litigation is also time consuming and would divert managements attention and resources away from
our operations and other activities. If we were not to prevail in any litigation, in addition to
any damages we would have to pay, we could be required to stop the infringing activity or obtain a
license. Any required license might not be available to us on acceptable terms, or at all. Some
licenses might be non-exclusive, and our competitors could have access to the same technology
licensed to us. If we were to fail to obtain a required license or were unable to design around a
competitors patent, we would be unable to sell or continue to develop some of our products, which
would have a material adverse effect on our business, financial condition and results of
operations. 
 Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK As described below, we are exposed to market risks related to changes in interest rates. Because
substantially all of our revenue, expenses, and capital purchasing activities are transacted in
U.S. dollars, our exposure to foreign currency exchange rates is immaterial. However, in the
future we could face increasing exposure to foreign currency exchange rates as we expand
international distribution of docosanol 10% cream and purchase additional services from outside the
U.S. Until such time as we are faced with material amounts of foreign currency exchange rate
risks, we do not plan to use derivative financial instruments, which can be used to hedge such
risks. We will evaluate the use of derivative financial instruments to hedge our exposure as the
needs and risks should arise. Interest rate sensitivity Our investment portfolio consists primarily of fixed income instruments with an average duration of
1.9 years as of March 31, 2005 (1.2 years as of September 30, 2004). The primary objective of our
investments in debt securities is to preserve principal while achieving attractive yields, without
significantly increasing risk. We classify our investments in securities as of March 31, 2005 as
available-for-sale and our restricted investments in securities as held-to-maturity. These
available-for-sale securities are subject to interest rate risk. In general, we would expect that
the volatility of this portfolio would decrease as its duration decreases. Based on the average
duration of our investments as of March 31, 2005 and 2004, an increase of one percentage point in
the interest rates would have resulted in increases in comprehensive losses of approximately
$84,000 and $119,000, respectively. 
 Item 4. CONTROLS AND PROCEDURES With the participation of the principal executive officer and principal financial officer of
Avanir Pharmaceuticals (the Registrant), the Registrants management has evaluated the
effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act
of 1934, Rules 13a-15(e) 40




---



##### Table of Contents



and 15(d)-15(e)), as of the end of the period covered by this report.
Based on that evaluation, the Registrants principal executive officer and principal financial
officer have concluded that:  
    Information required to be disclosed by the Registrant in this Quarterly Report on Form
10-Q and the other reports that the Registrant files or submits under the Exchange Act
would be accumulated and communicated to the Registrants management, including its
principal executive officer and principal officer, as appropriate to allow timely decisions
regarding required disclosure;
    Information required to be disclosed by the Registrant in this Quarterly Report on Form
10-Q and the other reports that the Registrant files or submits under the Exchange Act
would be recorded, processed, summarized and reported within the time periods specific in
the SECs rules and forms; and
    The Registrants disclosure controls and procedures are effective as of the end of the
period covered by this Quarterly Report on Form 10-Q to ensure that material information
relating to the Registrant and its consolidated subsidiary is made known to them,
particularly during the period in which the Registrants periodic reports, including this
Quarterly Report on Form 10-Q, are being prepared. Additionally, there were no changes in the Registrants internal control over financial reporting
(as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the Registrants fiscal
quarter ended March 31, 2005, that have materially affected, or are reasonably likely to materially
affect the Registrants internal control over financial reporting. 
 PART II OTHER INFORMATION 
 Items 1. LEGAL PROCEEDINGS Not applicable 
 Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Not applicable 
 Item 3. DEFAULTS UPON SENIOR SECURITIES Not applicable. 
 Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS The Annual Meeting of Shareholders of AVANIR Pharmaceuticals was convened on March 17, 2005, at
10:00 a.m. local time. There were issued and outstanding on January 21, 2005, the record date,
97,722,585 shares of Class A common stock, each share being entitled to one vote, constituting all
of our outstanding voting securities. There were present at the meeting in person or by proxy, our
shareholders who were the holders of 92,196,868 votes of our common stock entitled to vote
thereat, constituting a quorum. The following proposals received the number of votes set forth
below: Directors
    
    For
    
    
    WithholdStephen G. Austin, CPA
    
    
    87,782,864
    
    
    
    4,414,004Dennis G. Podlesak
    
    
    88,756,449
    
    
    
    3,440,419Paul G. Thomas
    
    
    88,771,199
    
    
    
    3,425,669
 41




---



##### Table of Contents



Proposals
    
    For
    
    
    Against
    
    
    Abstain2. Approve 2005 Equity Incentive
Plan
    
    
    29,165,798
    
    
    
    8,954,548
    
    
    
    523,2103. Approve Reverse Stock Split
within Stated Range
    
    
    74,358,533
    
    
    
    17,391,946
    
    
    
    446,3894. Ratification of Deloitte &
Touche LLP as Independent Auditors
    
    
    89,647,853
    
    
    
    2,076,182
    
    
    
    472,833
 
 Item 5. OTHER INFORMATION On March 22, 2005, we entered
into a Master Clinical Development Agreement with SCIREX Corporation (SCIREX) to engage SCIREX to
provide services to assist us in the execution of clinical
development projects. (See Exhibit 10.3) Our first project with
SCIREX was initiated on March 31, 2005 and is a Phase III clinical
trial of Neurodex in the treatment of diabetic neuropathic
pain. The clinical trial is being designed as a double-blind,
placebo-controlled, multicenter study to assess the safety and
efficacy of dextromethorphan and quinidine at two dose levels in the
treatment of pain of diabetic neuropathy. We estimate the project
will cost approximately $8.5 million, to be spent over a two-year
period. 
 Item 6. EXHIBITS Exhibits  10.1
    License Agreement, dated April 2, 1997, by and between IriSys
Research & Development, LLC and the Center for Neurologic Study.10.2
    Amendment to License Agreement, date April 11, 2000, by and between
IriSys Research & Development, LLC and the Center for Neurologic
Study.10.3
    Clinical Development Agreement,
dated March 22, 2005, by and between AVANIR Pharmaceuticals and
SCIREX Corporation.15.1
    Letter on unaudited interim financial information.31.1
    Certification of the Chief Executive Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002.31.2
    Certification of the Chief Financial Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 200232.1
    Certification of the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.32.2
    Certification of the Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002. 
 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized. Signature
    
    Title
    
    Date/s/ Gerald J. Yakatan, Ph.D.
    
    President and Chief
    
    May 13, 2005Gerald J. Yakatan, Ph.D.
    
    Executive
Officer
(Principal Executive Officer)/s/ Gregory P. Hanson, CMA
    
    Vice President, Finance and Chief
    
    May 13, 2005Gregory P. Hanson, CMA
    
    Financial
Officer
(Principal Financial and Accounting Officer)
 42




---



##### Table of Contents



EXHIBIT INDEX Exhibit No.
    
    Description10.1
    
    License Agreement, dated April 2, 1997, by and between IriSys
Research & Development, LLC and the Center for Neurologic Study.10.2
    
    Amendment to License Agreement, date April 11, 2000, by and between
IriSys Research & Development, LLC and the Center for Neurologic
Study.10.3
    
    Clinical Development Agreement,
dated March 22, 2005, by and between AVANIR Pharmaceuticals and
SCIREX Corporation.15.1
    
    Letter on unaudited interim financial information.31.1
    
    Certification of the Chief Executive Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 2002.31.2
    
    Certification of the Chief Financial Officer pursuant to Section 302
of the Sarbanes-Oxley Act of 200232.1
    
    Certification of the Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.32.2
    
    Certification of the Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
 43